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ABSTRACT 
 
 
Background 
Marfan Syndrome (MFS) and related disorders involves particularly skeletal, 
ocular and cardiovascular. Aortic aneurysms and dissections is the commonest 
feature of MFS leading to death. MFS caused by mutation in FBN1, and recently, 
also in TGFBR2 and TGFBR1. Mutation analysis in TGFBR1 gene is needed to 
know if the mutation is present in patient with MFS and related disorders. 
 
Methods 
One hundred and ninety four patients with MFS and related disorders, who have 
at least one major criteria of MFS and found to be negative for FBN1 and 
TGFBR2 mutation, are included. The DNA of the patients were then analyzed for 
TGFBR1 mutation by direct sequencing of the whole gene. The potency of 
pathogenicity of the mutation was predicted by referring to previous publication, 
amino acid changes, multiple alignment analysis and with the help of internet-
based software, PolyPhen and SIFT.  
 
Results 
Ten patients were found to carry TGFBR1 missense mutation. Each of them 
carried a different mutation, except 2 patients carried the same mutation. Seven 
out of nine of the mutations are considered pathogenic and 2 are not pathogenic. 
Aortic aneurysm is present in most patients with the mutation. None of  the patient 
with classic MFS has mutation in TGFBR1 gene.  
 
Conclusion 
Despite of mutation analysis on FBN1 and TGFBR2, mutation analysis on 
TGFBR1 in patient with MFS and related disorders is needed, especially on those 
who have aortic aneurysm. Knowledge of the presence of a mutation in an 
individual or in a family, may give a better guidance for comprehensive treatment 
including genetic counseling 
 
Keywords : Marfan Syndrome and related disorders, TGFBR1 mutation 
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ABSTRAK 
 
 
 
Latar Belakang  
Sindroma Marfan (MFS) dan kelainan terkait bermanifestasi di beberapa organ, 
terutama skeletal, okular dan kardiovaskular. Aneurysma dan diseksi aorta 
merupakan manifestasi yang paling sering mengakibatkan kematian pada MFS. 
MFS disebabkan oleh mutasi pada FBN1, dan akhir-akhir ini ditemukan juga 
disebabkan mutasi pada TGFBR2 dan TGFBR1. Analisis pada gen TGFBR1 
diperlukan untuk mengetahui apakah pada pasien Marfan Syndrome dan kelainan 
terkait lainnya terdapat mutasi pada gen TGFBR1.  
 
Metode 
Sebanyak 194 pasien dengan MFS dan kelainan terkait yang memiliki paling tidak 
satu kelainan mayor diikutsertakan dalam penelitian ini. Sebelumnya, pasien telah 
terbukti tidak memiliki mutasi pada FBN1 dan TGFBR2. Sekuensing pada gen 
TGFBR1 dilakukan untuk mengetahui adanya mutasi. Potensi patogenisitas 
mutasi dianalisis dengan mengacu pada publikasi-publikasi sebelumnya, melihat 
perubahan asam amino, melakukan multiple alignment analysis dan menggunakan 
software PolyPhen dan SIFT.  
 
Hasil 
Didapatkan 10 pasien dengan mutasi pada TGFBR1, dari keseluruhan pasien yang 
diperiksa. Setiap pasien memiliki 1 missense mutation yang berbeda, kecuali 2 
pasien dengan mutasi yang sama. Dari 9 missense mutations pada TGFBR1, 7 
diantaranya patogenik dan 2 nonpatogenik. Aneurisma aorta merupakan 
manifestasi klinik yang muncul pada hampir semua pasien dengan mutasi. Mutasi 
pada TGFBR1 tidak ditemukan pada pasien dengan MFS klasik.  
 
 
Kesimpulan 
Analisis mutasi TGFBR1 pada MFS dan kelainan terkait tanpa mutasi di FBN1 
dan TGFBR2 perlu dilakukan, terutama pada pasien dengan aneurisma aorta. 
Pengetahuan tentang keberadaan mutasi pada individu dalam keluarga dapat 
menjadi petujuk penting untuk penanganan yang komprehensif termasuk 
konseling genetika. 
 
 
Kata kunci : Sindroma Marfan dan kelainan terkait, mutasi TGFBR1  
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Chapter I 
INTRODUCTION 
 
I.1 Background 
Marfan Syndrome (MFS), a common autosomal dominant inherited 
disorder of fibrous connective tissue, has an estimated incidence of 1 : 
5,000.1,2 This syndrome involves many organ systems, particularly the 
skeletal, ocular and cardiovascular system. The most important life-
threatening complication in MFS is the occurrence of thoracic aortic 
aneurysms leading to aortic dissection, rupture, or both.3  
MFS is known to be one of the diseases in the spectrum of type-1 
fibrillinopathies, which constitute a range of clinical phenotypes that are 
caused by mutation in the gene for fibrillin-1 (FBN1 gene).1,2,4 In many cases, 
a diagnosis of MFS can be established by the Ghent criteria.5 However, the 
interpretation of these criteria is not always easy, due to the large clinical 
range of fibrillinopathies that overlap with MFS, and to age-dependent 
manifestations.  
The initial idea from previous publications about the pathogenesis of 
MFS concentrated on a static dominant negative model based on the concept 
of fibrillin-rich micro fibrils as purely architectural elements in the extra 
cellular matrix. Mutations in the fibrillin-1 gene (FBN1 gene), known to 
cause MFS, however, have not always been found in MFS patients. Recent 
 xix
findings of the pathogenesis of MFS demonstrate changes in growth factor 
signaling and other changes in matrix-cell interactions.4  
A connection of Marfan syndrome with the TGFβ signalling pathway 
was initially found in a study on mouse model of Marfan Syndrome with 
FBN1 mutation, and having lung emphysema as phenotypic manifestation. 
This mouse model showed increased TGFβ signalling.6 The involvement of 
TGFβ-receptor gene mutation in MFS has been shown in a Japanese patient 
with MFS who had a balanced chromosomal translocation involving 
chromosome 3p24. This locus had been found to show genetic linkage with 
MFS in a large French pedigree. The breakpoint in the Japanese patient 
disrupted the TGFBR2 gene. The same gene had a point mutation in the 
French Marfan family.7 Later research on TGFβ showed that the use of TGFβ 
antagonists such as TGFβ neutralizing antibody or the angiotensin II type 1 
receptor blocker, Losartan, reduce the growth of aortic aneurysm in a mouse 
model.8  
The proteins fibrillin-1, TGFBR1 and TGFBR2 take part in 
transforming growth factors β (TGFβ) signaling, thus mutations in one of 
these gene could cause similar phenotypes. TGFβ is stored in the extra 
cellular matrix in a latent form, bound to fibrillin 1 to form a complex. The 
complex is released by proteases, and the active TGFβ binds to its receptors 
on the cell surface (TGFβR1 and TGFβR2), leading to dimerization of the 
receptor. The kinase domain of the receptor is then activated and starting a 
signaling cascade in the cell regulating a number of cellular processes such as 
 xx
apoptosis, inflammation, proliferation and growth.9 Thus, TGFβ signaling 
will depend on the amount of latent TGFβ present in the tissue, strength of 
the binding of the complex and activity of TGFβ receptors.  
Mutations in the TGFBR1 and TGFBR2 genes have also been reported 
in individuals with Loeys-Dietz aortic aneurysms syndrome, a syndrome 
characterized by hypertelorism, bifid uvula and/or cleft palate, generalized 
arterial tortuosity with ascending aortic aneurysm, and worse cardiovascular 
risk profile than classic MFS.10 Another study reported TGFBR1 and 
TGFBR2 mutations in individuals with MFS-like phenotypes who previously 
tested negative for mutations in FBN1 gene.11 Mutations in TGFBR1 have 
been found in other syndromes related with MFS, e.g. Sphrintzen-Goldberg 
Syndrome, and in patients with Thoracic Aortic Aneurysms and Dissection 
(TAAD).6,11,12 So far, in total 22 different mutations have been found in the 
TGFBR1 gene.13 The phenotypes of patients having the mutations in TGFBR 
genes could not be clearly differentiated from each other.  
In this descriptive research we looked for and analyzed mutations in 
the TGFBR1 gene in patients referred to the DNA laboratory of Vrije 
Universiteit Medisch Centrum Amsterdam (VUmc), The Netherlands, with a 
clinical suspicion of MFS or related disorders, who did not have a FBN1 or 
TGFBR2 mutation.  
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I.2 Research Questions 
       I.2.1 General research question :  
What kind of mutations can be found in the TGFBR1 gene in 
people with clinical Marfan Syndrome, and other related disorders with 
negative FBN1 and TGFBR2 mutations? 
  
I.2.2  Specific research question 
1. Is there any mutation in the TGFBR1 gene as a candidate gene for 
Marfan Syndrome and related disorders with negative FBN1 and 
TGFBR2 mutations, and if yes, what kind of mutation is it? 
2. How is the prediction of pathogenicity of the mutation? 
3. How is the distribution of clinical phenotype on genotype?  
4. Is there any clinical characteristic that may lead to TGFBR1 gene 
mutation analysis? 
 
I.3 Research purposes 
 I.3.1 General purposes : 
To identify and analyze the kind of mutations in the TGFBR1 gene 
as candidate gene for Marfan Syndrome and related disorders with 
negative FBN1 and TGFBR2 mutations, and to see the distribution of 
clinical phenotype on the genotype .  
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I.3.2 Specific purposes : 
1. To detect the mutations in the TGFBR1 gene in a person with Marfan 
Syndrome and related disorders with negative FBN1 and TGFBR2 
mutations.  
2. To analyze the kind of mutations and the potential pathogenic effect 
of the mutations. 
3. To see the distribution of clinical phenotype on the genotype.  
4. To see whether there is a clinical characteristic that may lead to 
TGFBR1 mutation analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xxiii
Chapter II 
LITERATURE REVIEW 
 
II.1 MARFAN SYNDROME AND RELATED DISORDERS 
Patients with Marfan Syndrome (MFS) may have abnormalities in 
several different organ systems, but mostly in skeletal, ocular and 
cardiovascular systems.1 Skeletal features of MFS are increased height, 
disproportionately long limbs and digits, elbow contracture, anterior chest 
deformity, mild to moderate joint laxity, vertebral column deformity (scoliosis 
and thoracic lordosis) and a narrow, high palate with crowding of the teeth. 
Ocular findings in MFS include increased axial globe length, corneal flatness 
and (sub) luxation of the lenses (ectopia lentis). Mitral valve prolaps, mitral 
regurgitation, dilatation of the aortic root and aortic regurgitation are 
cardiovascular features. Aneurysm of the aorta and aortic dissection are the 
major life-threatening cardiovascular complications. Mostly, this feature 
brings MFS into special attention. Other common features are striae distensae, 
pulmonary blebs, which predispose to spontaneous pneumothorax and spinal 
arachnoid cysts or diverticula. By CT or MRI scanning also dural ectasia can 
be found. The early-onset severe MFS, neonatal MFS, presents with serious 
cardiovascular abnormalities as well as congenital contractures. MFS is also 
associated with a high prevalence of obstructive sleep apneu.1,2,14,15 
The diagnosis of MFS is based on a set of clinical diagnostic criteria, 
termed The Ghent Criteria.5 In clinical practice, these criteria are not always 
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obvious, since there are many conditions overlapping with MFS and because 
of age-dependent manifestation. The overlapping conditions are Familial 
Aortic Aneurysm, Bicuspid Aortic Valve with Aortic Dilatation, Familial 
Ectopia Lentis, MASS phenotype, Marfan Body Type, Mitral Valve Prolapse 
Syndrome, Congenital Contractural Arachnodactily (Beals syndrome), 
Stickler syndrome, Shprintzen-Goldberg Syndrome, Loeys-Dietz Syndrome 
and Ehlers-Danlos syndrome.1,2,4,14,15 The clinical features of those overlap 
disorders are described in the table below : 
Table 1. Clinical features of some overlapping disorders 
No. Disorders Clinical Features 
1. Familial Aortic Aneurysm Aortic aneurysms, aortic dissection, familial 
2. Loeys-Dietz Syndrome 
Widely-spaced eyes (hypertelorism), bifid uvula, 
generalized arterial tortuosity with widespread arterial 
aneurysms and dissection 
3. Ehlers-Danlos syndrome 
Skin hyperextensibility, joint hypermobility, easy 
bruising, tissue fragility, mitral valve prolapse, aortic 
dilatation (uncommon) 
4. MASS phenotype 
Mitral valve prolapse, aortic root diameter at the 
upper limit of normal, stretch mark (striae), skeletal 
features of Marfan (joint hypermobility, pectus 
excavatum/carinatum, scoliosis) 
5. Marfan Body Type Tall, long-thin arms & leg, long-thin fingers, scoliosis, hypermobility of the joint 
6. Mitral Valve Prolapse Syndrome Mitral valve prolapse 
7. 
Congenital 
Contractural 
Arachnodactily 
Joints contracture, crumpled ears, arachnodactily, 
scoliosis, kyphoscoliosis, osteopenia, 
dolichostenomelia, pectus excavatum or carinatum, 
muscular hypoplasia, micrognathia, high-arched 
palate  
8. 
Shprintzen-
Goldberg 
Syndrome 
Omphalocele, scoliosis, laryngeal/pharyngeal 
hypoplasia, mild dysmorphic face, learning 
disabilities 
9. Familial Ectopia Lentis 
Ectopia lentis, with the signs of myopia, 
astigmatisms, and blur vision 
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 This table shows some of the disorders that have overlapping phenotypes 
with Marfan Syndrome. 
 
II.2 TGFβR1, TGFBR1 GENE AND CONTROL OF TGFβ SIGNALLING 
Fibrillin and TGFβR are taking part in the TGFβ signalling pathway. 
Fibrillin is the major constitutive element of the extracellular microfibrils 
which has a crucial role in regulating TGFβ bioavailability in the vascular 
system.4 The bioavailability of active TGFβ is regulated at multiple levels, 
including secretion and interaction with extra cellular matrix components.  
 
 
 
 
 
 
 
 
 
 
Figure 1. Regulation of TGFβ bioavailability (taken from Nature Reviews on 
Molecular Cell Biology 2007) 
Synthesis and secretion (a) : TGFβ is synthesized as a pre-pro-protein, which undergoes 
proteolytic processing in the rough endoplasmic reticulum (1). Two monomers of TGFβ 
dimerize through disulfide bridges (2). The pro- TGFβ dimer is then cleaved by furin 
convertase to yield the small latent TGFβ complex (SLC), in which the latency-associated 
 xxvi
peptide (LAP) and the mature peptide are connected (3). This processing step is inhibited by 
emilin-1. The large latent TGFβ binding protein (LTBP) is attached, and form the large latent 
TGFβ complex (LLC) (4). The N-terminal and hinge region of LTBP interact covalently with 
extra cellular matrix component, such as fibronectin. The C-terminal region of LTBP interacts 
non covalently with the N-terminal region of fibrillin-1.9  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Regulation of TGFβ bioavailability--continued (taken from Nature 
Reviews on Molecular Cell Biology 2007) 
Activation and receptor binding (b) : An internal fragment of fibrillin-1 released by 
proteolysis mediated by elastases at sites (indicated with black arrowheads) (5), interacts 
with N-terminal region of fibrillin-1 to displace LTBP and release LLC (6). The LLC can be 
targeted to the cell surface by binding to integrins via RGD sequence (blue regions) in LAP. 
Bone morphogenetic protein-1 (BMP1) can cleave two sites in the hinge region of LTBP, 
which results in the release of LLC (7). Matrix metalloprotease-2 (MMP2) and other 
proteases can cleave LAP to release mature TGFβ (red). Mature TGFβ can then bind to its 
receptors, TGFβR2 and TGFβR1.9 
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Transforming growth factor-β plays a pivotal role in vascular 
remodeling and the resolution process of angiogenesis. TGFβ regulates 
cellular processes by binding to a heterodimeric complex of the type I and 
type II serine/threonine kinases receptors (TGFβR1 and TGFβR2). Once the 
active TGFβ family member is released from the extra cellular matrix, it 
signals via the receptors, the TGFβR2 and TGFβR1 (also known as ALK5; a 
type I receptor).   
 The type I receptor acts downstream of the type II receptor and 
propagates the signal to the nucleus by phosphorylating specific members of 
the SMAD family, receptor-regulated(R)-Smads.9  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3. Signal transduction by TGFβ family members (taken from Nature 
Reviews on Molecular Cell Biology 2007) 
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The type I receptor acts downstream of the type II receptor and 
propagates the signal to the nucleus by phosphorylating specific members of 
the SMAD family, receptor-regulated(R)-Smads.9 The phosphorylated 
SMADs will then gives signal to the nucleus, and regulates the transcription 
steps of the genes which play roles in differentiation, growth inhibition, 
deposition of extra cellular matrix and apoptosis. 
TGFβR1 (ALK5) is required for TGFβ-ALK1 activation, whereas 
ALK1 inhibits intracellular ALK5-SMAD signaling. The differential 
activation of these two distinct type-I receptor pathways by TGFβ provides the 
endothelial cells with an intricate mechanism to precisely regulate, and even 
switch between, TGFβ-induced biological responses. For example, TGFβ-
ALK1 activation leads to stimulation of endothelial cell proliferation and 
migration, whereas TGFβ-ALK5 activation inhibits these responses.9  
The TGFBR1 gene is also known as activin A receptor like kinase, or  
serine/threonine-protein kinase receptor R4 gene. The DNA size is 
approximately 45kb long, the mRNA size is 2308bp, contains of 9 exons and 
is located on chromosome 9q22.33.16,17 The schematic diagram of The 
TGFBR1 gene with its exons and introns is presented in the figure below : 
contains of 9 exons and is located on chromosome 9q22.33.16,17  
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 Figure 4. Schematic diagram of TGFBR1 gene with its exons and introns. 
The gene starts from base 3528940 until 3573835, the size is 44.90 Kb, there are 9 exons, 
with the transcript size 2308 bp. The NCBI code for this gene is NM_004612. 
 
The gene contains 14 different gt-ag introns. Transcription produces 12 
different mRNAs, 9 alternatively spliced variants and 3 unspliced forms. 
There are 4 probable alternative promoters, 2 non overlapping alternative last 
exons and 10 validated alternative polyadenylation sites.18  
The protein domains of TGFBR1 consist of : extra cellular domain, 
transmembrane domain, cytoplasmic domain, glycine-serine rich domain, and 
serine-threonine kinase domain. These domains are highly conserved across 
species.16 The schematic diagram of TGFBR1 domains is described in figure 
below : 
 
 
 
Figure 5. The schematic diagram of TGFBR1 domains, exons and 
domain organization  
Schematic figure of TGFBR1 showing extracellular domain (yellow), transmembrane 
domain (blue), serine-threonine kinase domain (red), intracellular domain without specific 
function (grey) and glycine-serine-rich domain (green)10,16 
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Mutations in the genes encoding transforming growth factor-β receptor 
have been found in patients with MFS and Marfan-like connective tissue 
disorders. Some syndromes are associated with such mutations including 
Marfan Syndrome itself,11,19 Loeys-Dietz Syndrome (LDS)  (TGFBR2 and 
TGFBR110,20) and Sphrintzen-Goldberg Syndrome (TGFBR2.12,21). Mutations 
in TGFBR2 and TGFBR1 were also found in patients with Familial Thoracic 
Aneurysms and Dissections.11 
 
II.3 ANALYSIS OF DNA SEQUENCE TO DECIDE PATHOGENICITY 
Some steps are needed to decide whether the variation in DNA 
sequence is necessarily pathogenic or not.  
The databases of mutation, such as LSDBs (Locus-specific databases), 
HGMD (Human Gene Mutation Database), UMD (Universal Mutation 
Database), OMIM (Online Mendelian Inheritance in Man), dbSNP (database 
of Single Nucleotide Polymorphisms) / Ensembl database can be used for 
reference. For TGFBR1 gene, we can look for the previous mutations that 
have been found, in UMD (Universal Mutation Database : www.umd.be). The 
dbSNP/Ensembl database (www.ensembl.org) can be used to check whether 
the point mutation we found is a polymorphism or not.13,22  
By looking at the type of DNA sequence changes, we can predict their 
significancy in affecting gene function.  
Deletions of the whole gene, nonsense mutation (a form of 
nonsynonymous substitution where a codon specifying an amino acid is 
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replaced by a stop codon) and frameshift mutation (a mutation that alters the 
normal translational reading frame of an mRNA by adding or deleting a 
number of bases that is not a multiple of three), are almost certain to destroy 
gene function.23 
Mutation that change the conserved splice site (GT…AG nucleotides) 
affects splicing, and will usually abolish the function of the gene. In silico 
predictions for splice site are available, for example Splice Sequence Finder 
(Montpelier) www.umd.be/SSF, GeneSplicer Web Interface 
www.tigr.org/tdb/GeneSplicer/gene_spl.html, etc.23 
A missense mutation is more likely to be pathogenic if it affects a part 
of the protein domain known to be functionally important.23  
Changing of an amino acid is more likely to affect function if that 
amino acid is conserved in related genes, orthologs (genes present in different 
genomes which are directly related through descent from a common ancestor) 
or paralogs (genes present in a single genome as a result of gene duplication). 
If two or more sequences show sufficient degree of similarity (sequence 
homology), they can be assumed to be derived from the same ancestor. The 
higher the degree of similarity, the gene are more conserved, means that the 
gene has very important role through evolution. The mutation at that point will 
be strongly suspicious to be pathogenic. Multiple alignment analysis is 
comparing the amino acid sequence of certain protein with the closest similar 
sequences from some species. By looking at the position and the presence of 
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amino acid, we can decide whether the amino acid is conserved across the 
species or not.23,24  
Amino acid substitutions are more likely to affect function if they are 
nonconservative. Nonconservative substitutions result in replacement of one 
amino acid by another that is chemically not similar. For example, the change 
from a polar to a non polar amino acid, or an acidic to a basic.23 
Another way to predict the potential pathogenicity of a mutation is by 
using in silico prediction analysis. There are some software available in the 
internet, that can be used to do the prediction, for example PolyPhen 
(Polymorphisms Phenotyping) and SIFT (Sorting Intolerance From 
Tolerance). PolyPhen (http://coot.embl.de/PolyPhen/)25, is an automatic tool 
for prediction of possible impact of an amino acid substitution on the structure 
and function of human protein. This prediction is based on empirical rules 
which are applied to the sequence, phylogenetic and structural information 
characterizing the substitution. A protein identifier from proteins database, 
such as SWALL is needed before entering the amino acid substitution. This 
program will then identify the sites in which the new amino acid replaced, do 
multiple alignment, and calculate the so-called profile matrix by Position-
Specific Independent Counts (PSIC). The PSIC score will be used as one of 
prediction parameter. A Protein Quarternary Structure (PQS) database is also 
used as another consideration. The results of PolyPhen can be : probably 
damaging (it is with high confidence supposed to affect protein function or 
structure), possibly damaging (supposed to affect protein function or 
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structure), benign (most likely lacking any phenotypic effect) and unknown (in 
some rare cases, when the lack of data do not allow PolyPhen to make a 
prediction).26 The detail guideline to interpreting PolyPhen result is attached in 
the attachment.  
SIFT BLink is a sequence-homology-based tool that sorts intolerant 
from tolerant amino acid substitutions and predict whether an amino acid 
substitution at a particular position in a protein will have a phenotypic effects. 
SIFT BLink bases its prediction on sequence data alone and does not depend 
on knowledge of protein structure and function. The results of SIFT BLink 
prediction are affect protein function and tolerated (means that the substitution 
can be tolerated, thus does not affect protein function). The sequence data for 
specific protein is inputted, and will be followed by some steps in which SIFT 
BLink process the data input to prediction. Substitutions at each position with 
normalized probabilities less than a chosen cutoff are predicted to be 
deleterious, while those greater than or equal to the cutoff are predicted to be 
tolerated.24  
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II.4. THEORETICAL SCHEME 
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Notes :  
- TGFβ   = Transforming growth factor beta 
- LTBP  = Latent transforming growth factor binding protein 
- BMP  = Bone morphogenetic protein 
- TGFBR1 = Transforming growth factor beta receptor type 1 
- TGFBR2 = Transforming growth factor beta receptor type 2 
 
 
II.5 CONCEPTUAL SCHEME 
 
 
 
 
    
 
  
 
 
 
  
 The conseptual scheme of this research 
 
 
 
 
 
 
 
 
 
 
 
 
TGFBR1 gene 
Mutations at 
any specific 
sites
Marfan Syndrome 
and related 
disorders 
phenotypes 
 xxxvi
Chapter III 
RESEARCH METHODOLOGY 
 
III.1. Research field 
  This research is in the field of medical genetics. 
 
III.2. Research location 
This research was held in the DNA Diagnostic Laboratory of Vrije 
Universiteit Medisch Centrum (VUmc), Amsterdam, The Netherlands for DNA 
analysis. 
 
III.3. Research period 
  This research has been conducted in one year. 
 
III.4. Research design 
  This is a descriptive study. 
 
III.5. Research methods 
III.5.1. Population 
The population of this research is the DNA samples of patients 
with Marfan Syndrome and related disorders which have been reffered to 
DNA Diagnostic Laboratory of VUmc Hospital Amsterdam, The 
Netherlands from the year 1998-2008.  
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III.5.2. Samples 
The DNA samples were donation with permission from Gerard 
Pals, PhD as the principal investigator of Connective Tissue Disorders 
research in the DNA Diagnostic Laboratory of VUmc Hospital Amsterdam, 
The Netherlands. All of the samples used in this research are part of 
Connective Tissue Disorders research project, and have been consent to be 
included in research (informed consent form attached).  
We selected the first 194 unrelated patient’s from VUmc’s DNA 
Diagnostic Laboratory database by their registration numbers, which have 
been referred as Marfan Syndrome, suspected Marfan Syndrome, or related 
disorders. The phenotypic characteristics of the patients were then traced 
from their laboratory request form.  
III.5.2.1. Inclusion criteria : 
1. Having at least one major criterion of MFS  
2. Found to be negative for FBN1 and TGFBR2 mutations.  
III.5.2.2. Exclusion criteria : 
1. Not enough amount of DNA available for complete 
examination. 
III.5.2.3. Minimum sample requirement : 
This is the first research on TGFBR1 gene in Marfan Syndrome 
and related disorders patients in The Netherlands. Another 
research on TGFBR1 revealed a frequency of 4% among 
numbers of patients.19 Sample amount determination for 
estimation of proportion in population is as below 28 : 
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            P=0.04; Zα= 1.96; d=0.10 
     
         n= (1.96)2 x 0.04 x (1-0.04) = 153 
      (0.10) 2 
  Notes : 
P = the proportion of TGFBR1 mutations found in previous study = 0.0419 
d = precision level = 0.10 
α = significancy level = 0.95, Zα = 1.96 
 
The minimum sample which is required is 153 samples.  
III.6. Research Variables : 
  The variables of this research are : 
1. Clinical phenotypes of Marfan Syndrome and related disorders 
Scale : nominal 
2. Mutation in TGFBR1 gene 
Scale : nominal 
3. Pathogenicity of mutation 
Scale : nominal 
III.7. Operational Definitions 
1. Marfan Syndrome : a group of clinical signs, fulfilling the Revised  
Criteria of Marfan Syndrome (Ghent Criteria).  
2. Ghent Criteria of Marfan Syndrome : clinical criteria for diagnosing 
Marfan Syndrome (details attached in the attachment). For the index 
cases, major criteria in at least 2 different organ systems and 
involvement in third organ is needed, if the family/genetic history is 
not contributory. For a relative of an index case, one major criterion in 
n = Zα2 PQ 
           d2 
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an organ system and an involvement of second organ is needed if a 
major criterion in family history is present. 
3. Suspected MFS : incomplete Ghent criteria with more than one signs 
which are mentioned in the criteria. 
4. Related disorders of Marfan Syndrome : disorders that share several 
symptoms with Marfan Syndrome, including Loeys-Dietz Syndrome, 
Ehler-Danlos Syndrome vascular type, Aortic aneurysms and 
dissection, Bicuspid Aortic Valve with Aortic Dilatation, Familial 
Ectopia Lentis, MASS phenotype, Mitral Valve Prolapse Syndrome, 
Congenital Contractural Arachnodactily (Beals syndrome), Stickler 
syndrome, Shprintzen-Goldberg Syndrome, joint hypermobility, etc. 
The clinical features of these disorders are in the attachment. 
5. Phenotype : all the clinical signs found in Marfan Syndrome and 
related disorders patients 
6. Mutation : an alteration in DNA sequence.  
7. Pathogenicity : the condition in which the mutation will results in 
protein changes thus causing disease, predicted by the type of amino 
acid changes, domain localization, multiple alignment, and prediction 
results of internet-based software, with consideration to literature. 
III.8. Mutation Detection 
III.8.1 Amplification 
In order to get enough amount of DNA fragment to be visible in 
the gel and have strong enough signal in sequencing, the TGFBR1 
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gen in the DNA need to be amplified. The genomic DNA reference 
sequence for TGFBR1 gene amplification is ENSG00000106799.29 
PCR was done for 9 exons of TGFBR1, on genomic DNA, with the 
primers below : 
Table 2 : Primers sequence for amplifying the TGFBR1 gene exon 1-9 
No. Exons Forward/Reverse Primer’s sequence (5’>3’) Product length (base 
pairs) 
1. 1 Forward AGTTACAAAGGGCCGGAGCGAGG 302 
2. 1 Reverse TTTGAGAAAGAGCAGGAGCGAGCCA  
3. 2 Forward TTGGGCTTCCACGTGTATGTG 576 
4. 2 Reverse GTCACTTCTTGCCTCTAAACG  
5. 3 Forward GCCACCTACAGTGTTTTTGTCGT 530 
6. 3 Reverse TTATACCACCATGGAGCTGACTTAT  
7. 4 Forward GTATCAGTTTTCTGGGTCACTCA 462 
8. 4 Reverse ATTCGACTTAATGGGTCTAATCTAC  
9. 5 Forward CAGTGTGTGACTCAGGATTG 340 
10 5 Reverse CCACCTTCTATTTTCATAGACATT  
11. 6 Forward AATGCCGTAAGTATTGTAGGTCAT 426 
12. 6 Reverse TCTTCTTACCTGTTGGCAATCTA  
13. 7 Forward TTTTGTGGGATTTAGTTGACATCA 448 
14. 7 Reverse TTTCTCTGGCACTCGGTGA  
15. 8 Forward AAGGTGTGGGTGGAATATCAACTC 512 
16. 8 Reverse GGCCCTTTCAATGTGCTTACAAT  
17. 9 Forward TCGGCCTTTTCAGGTTTGCTAA 584 
18. 9 Reverse CCTGGGAAAGAAGCGTTCATAG  
19. 9 Forward2 TTGTAGGCCTTGAGAGTAATGGCTA 383 
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Table shows the sequence of each primer (forward and reverse) which is used to amplified exon 1 
to 9 of TGFBR1 gene, and the product size. 
Notes : For exon 9 we used 2 forward primers, because of a long T-
stretch in the DNA sequence. A long T-strech is vulnerable to deletion, so 
that the sequence output will be messy, and the mutation after the deleted-T 
will not be detected. The other forward primer which start after T-stretch 
will prevent the undetected mutation. 
At the 5’ end of each primer an M13 tail primer sequence forward or 
reverse (M13 primer, INVITROGEN, Cat.No.N520-02 (F) and N530-02 
(R)) was added, in order to simplify the sequencing procedure. With M13 
tail primer attached in the PCR primer, the amplified fragment will start 
from M13 sequence, so that in cycle-sequencing reaction we will need only 
M13 tail primer to amplify all exon, and not different primer for different 
exons. The sequences of M13 tails primers are as below :  
Table 3 : M13 primers sequence 
No. Primer’s name Sequences 
1. M13 forward GTAAAACGACGGCCAG 
2. M13 reverse CAGGAAACAGCTATGA 
The table shows the sequences of M13 tail primer, which is attached to PCR primer and 
used in cycle-sequencing reaction. 
 
Five microliter DNA solution (DNA concentration : 20 ng/µl) was 
added into 25 µl PCR mixture, which contained 0.2 µl of 25 mM dNTPs, 
0.75 µl of 50 mM MgCl2 (Invitrogen), 1µl of 10pmol/µl each primer 
(Invitrogen), 2.5 µl of 10x PCR buffer (Invitrogen), 0.2 µl of 5U/µl Taq 
DNA polymerase (Platinum Taq DNA Polymerase, Invitrogen, 
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Cat.No.10966-034) and 15.35 µl H2O. The thermal profile included initial 
denaturation for 5 minutes at 940C, followed by 35 cycles of denaturation (1 
minute at 940C), annealing (1 minute at 650C), and extension (1 minute at 
720C), in PE9700 Applied Biosystem thermocycler. Five microliters of each 
sample was then runned on an 2% agarose gel with 100V for 30 minutes and 
stained with ethidium bromide, to confirm PCR amplification product (the 
size of PCR product as described in table 1). 
III.8.2 DNA sequencing 
The purpose of sequencing is to determine the order of the nucleotides 
of a gene.  
Prior to sequencing, the PCR products were purified from excess 
primers and dNTPs molecule by a mixture of Exo 1 (Exonuclease 1, USB 
Corp. Cleveland, Ohio, Cat.No.70073X) and SAP enzyme (Shrimp Alkaline 
Phosphatase, USB Corp. Cleveland, Ohio, Cat.No.70092Y). Five microliters 
of PCR were taken into the reaction, together with 0.25 µL SAP, 0.25 µL 
Exo1 and 1.5 µL HPLC H2O. The mixture was then incubated in a 
thermocycler with a program of 30 minutes in 370C followed by 15 minutes 
in 800C. Then diluted with 15 µL HPLC H2O, and was added sequencing 
primer (forward or reverse) as much as 1 µL.  
Sequencing reactions used the BigDye Terminator Cycle Sequencing 
kit (version 3 Applied Biosystems. Foster City, CA, USA, Cat.No.4737458) 
on an ABI 3730 Genetic Analyzer (Applied Biosystems, Foster City, Ca, 
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USA). Seven microliter of BigDye mix, which contained of 0.5 µL BigDye 
V3.1 reaction mix, 1.75 µL BigDye V3.1 5x sequencing buffer and 4.75 µL 
HPLC H2O, were taken into reaction together with 3 µL of SAP-Exo1-PCR 
product mixture. Then runned in a thermocycler with a program of 960C 10 
minutes denaturation, 550C 5 seconds annealing, 600C 4 minutes elongation, 
25 cycles.  
The products of sequencing reaction were then precipitated using 
ethanol precipitation method in order to remove unincorporated dye 
terminators. The product would then be added with 20 µL formamide, 
heated in thermocycler on 940C for 2 minutes and cooled down to 40C, and 
put in the sequencer (ABI 3730 Genetic Analyzer, Applied Biosystem)  
 
III.9. Mutation Analysis 
We compared the sequence of patients with the reference sequence. 
The variant numbering is based on the cDNA sequence 
(ENST00000374994),30 where +1 corresponds to the nucleotide A of ATG, 
the translation initial codon.  
The UMD database of TGFBR1 mutations, the Ensemble SNPs 
database of polymorphisms and the previous reports on TGFBR1, were used 
to confirm the DNA sequence variants. Whenever the variant was not 
mentioned as polymorphism in one of those references, we did the analysis 
based on the changes in amino acid types, domain conservation in some 
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species, protein structure and previous publications on the mutations. 
Internet-based software programs to predict the possible impact of amino 
acid substitutions were also used to help the analysis.  
The first program was PolyPhen (http://coot.embl.de/PolyPhen/)25, a 
web-based tool to predict the possible impact of amino acid substitution on 
the structure and function of the protein. The data query needs a protein 
identifier which codes specific protein in the protein database. The protein 
identifier in SWALL-protein database for TGFBR1 is P36897.31 We use 
default query parameters for protein quaternary structure (PQS) databases 
and performing calculations for all hits. The second program we used was 
SIFT Blink27, a sequence homology-based amino acid substitution 
prediction method (available at 
http://blocks.fhcrc.org/sift/SIFT_BLink_submit.html). We applied 
gi:4759226 protein sequence of TGFBR1 by using parameter “best BLAST 
hit to each organism” and omitting sequences 100% identical to query. 
Results were reported as “affects protein function” or “tolerated” according 
to this analysis.  
To help predict the affect of mutation on the splice site, we used web-
based tool Human Splicing Finder32 (available at www.umd.be/HSF/) which 
analyzed the sequence towards the presence of enhancer motifs, silencer 
motifs, exonic splicing regulatory sequences, potential branch points and 
potential splice sites. 
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III.10. Research Flow 
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III.10. Research Flow (continued) 
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III.11. Data Analysis 
  The data will be analyzed descriptively for the clinical features of 
the patients, the number of patients in each diagnosis group, the mutations that 
have been found and the distribution in each exon and domain, the amino acid 
type changes and the prediction of pathogenicity with their multiple sequence 
alignment, and the polymorphisms and unclassified variants. The details are as 
below : 
1. The clinical features of the patients; the list of mutations, amino acid-
type changes and the prediction results from PolyPhen and SIFT; the 
list of polymorphisms and unclassified variants and the distribution of 
TGFBR1 mutations on clinical diagnosis will be presented in tables.  
2. The number of patients in each diagnosis will be presented in graph. 
3. The distribution of mutations in each exon and domain will be 
presented in schematic figure. 
4. The multiple sequence alignment will be presented in figure. 
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Chapter IV 
RESULTS 
 
IV.1 Clinical diagnosis of patients 
The patient samples included in this study came from many centers, 
inside and outside The Netherlands, such as Belgium and United Kingdom. 
All the DNA samples included are a donation with permission from DNA 
diagnostic laboratory of Vrije Universiteit Amsterdam, The Netherlands. 
The clinical information of patients described here has been collected 
from clinical observations that have been mentioned in the laboratory 
request form.  
Tabel 4. Detail Clinical Features of Marfan Syndrome and Related 
Disorders Patients based on Organ System presented in Percentage 
 
No. Clinical Features Number of Patients 
Percentage 
from total 
194 
patients 
  Skeletal      
1 Marfanoid habitus 18 9.28% 
2 Joint hypermobility 16 8.25% 
3 Pectus excavatum/carinatum 11 5.67% 
4 Increased span-height ratio 11 5.67% 
5 Tall and thin 9 4.64% 
6 Scoliosis 9 4.64% 
7 Arachnodactily 7 3.61% 
8 High and narrow palate 5 2.58% 
9 Positive fingers signs (thumb sign & wrist sign) 3 1.54% 
10 Kyfosis 2 1.03% 
11 Flat foot 2 1.03% 
12 Shoulder luxation 2 1.03% 
13 Spondilolisthesis 1 0.52% 
14 Contracture of the hands 1 0.52% 
15 Palatoschizis 1 0.52% 
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No. Clinical Features Number of Patients 
Percentage 
from total 
194 
patients 
16 Crowded teeth 1 0.52% 
17 Skeletal abnormalities (unspecified) 26 13.40% 
  Cardiovascular     
1 Aortic aneurysms 137 70.62% 
2 Aortic dissection 24 12.37% 
3 Mitral Valve Prolaps 5 2.58% 
4 Aortic valve insufficiency 4 2.06% 
5 Pulmonary stenosis 2 1.03% 
6 Dissections of artery coronaria 2 1.03% 
7 Aneurysms of other big vessel 1 0.52% 
8 Persisten Ductus Arteriosus 1 0.52% 
9 Mitral Insufficiency 1 0.52% 
10 Varices 1 0.52% 
11 Heart problem (unspecified) 1 0.52% 
  Occular     
1 Myopia 4 2.06% 
2 Lens subluxation 4 2.06% 
3 Ectopia Lentis 3 1.54% 
4 Flat cornea 1 0.52% 
5 Retinal detachment 1 0.52% 
6 Eye abnormality (unspecified) 7 3.61% 
  Lung     
1 Spontaneous pneumothorax 3 1.54% 
2 Lung abnormality (unspecified) 2 1.03% 
  Dura     
1 Dural ectasia 6 3.09% 
  Skin & Integumen     
1 Striae 5 2.58% 
2 Thin skin 2 1.03% 
3 Uterus & Bladder prolaps 2 1.03% 
4 Hernia inguinalis 1 0.52% 
5 Skin abnormality unspecified 4 2.06% 
  Others     
1 Uvula bifida 2 1.03% 
2 Mental retardation 1 0.52% 
Notes : one patient may have more than one clinical features. 
The clinical diagnoses of the patients were based on clinical findings 
and matched with Ghent Criteria. A diagnosis of MFS was based on Ghent 
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Criteria. Incomplete Ghent Criteria, or having at least one major criterion in 
an organ system with minor criterion of another organ, or more than one 
minor criterion, would be considered as Suspected MFS. The patients with 
only specific clinical features (such as only has aortic aneurysm, ectopia 
lentis, dural ectasia or joint hypermobility) would be grouped as the clinical 
findings, recognized as Marfan Syndrome, Suspected MFS, Aortic 
Aneurysms and/ Dissections, Familial Aortic Aneurysms and/ Dissections, 
Ectopia Lentis, Dural Ectasia, Joint Hypermobility.  
 The summary of patients based on clinical diagnosis are presented in 
the graph below :  
 
 
 
 
 
 
 
 
 
 
Figure 6. Bar graph showing the number of patients in each group 
Most of the patients included in this research were diagnosed as suspected MFS (78 
patients), followed by aortic aneurysms and dissection (60 patients) and familial cases of 
aortic aneurysms and dissections (42 patients). 
 
 
 
10
78
60
42
2 1 10
10
20
30
40
50
60
70
80
Marfan
 Synd
rome
Suspe
cted M
FS
Aortic
 Aneu
rysm 
& Diss
ection
Famili
al Aor
tic An
eurys
m & D
issect
ion
Ectop
ia Len
tis
Dural 
Ectas
ia
Joint h
yperm
obility
 li
IV.2 TGFBR1 mutation detection results 
On sequencing all 9 exons of TGFBR1, a total of 9 mutations, 7 
different polymorphisms and 3 unclassified variants in TGFBR1 were found. 
The mutations were found in 10 patients. The 9 mutations, occured in 7 
different exons (see table 5).  
We did analysis on mutations by observing the amino acid changes, 
looking at the conservation in 11 different species and the domain 
localization, and using internet-based software to predict the pathogenicity 
of amino acid changes.  
The list of mutations, amino acid-type changes and the prediction 
results from PolyPhen and SIFT are presented in table 3 below : 
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Table 5. Mutations, amino acid type changes and Predicted Functional Effects of amino acid changes 
 
No Location Mutation Mutation Type AA changes PolyPhen SIFT Diagnosa 
1 Exon 2 c.113G>A; p.C38Y 
Missense 
mutation Po N > Po N 
Probably 
damaging Tolerated Familial aortic aneurysm &/ dissection 
2 Exon 3 c.451C>T; p.R151C 
Missense 
mutation Po B > Po N Benign Tolerated Suspected Marfan Syndrome 
3 Exon 4 c.605C>T; p.A202V 
Missense 
mutation 
NPo N > NPo 
N Benign 
Affects 
protein 
function 
1. Suspected Marfan Syndrome 
2. Familial aortic aneurysm &/ 
dissection 
4 Exon 5 c.839C>T; p.S280L 
Missense 
mutation Po N > NPo N 
Possibly 
damaging Tolerated Suspected Marfan Syndrome 
5 Exon 5 c.958A>G; p.I320V 
Missense 
mutation 
NPo N > NPo 
N 
Possibly 
damaging Tolerated Suspected Marfan Syndrome 
6 Exon 5 c.965G>A; p.G322D 
Missense 
mutation NPo N > Po A Benign Tolerated Aortic aneurysm &/ dissection 
7 Exon 6 c.980C>T; p.P327L 
Missense 
mutation 
NPo N > NPo 
N 
Probably 
damaging 
Affects 
protein 
function 
Suspected Marfan Syndrome 
8 Exon 8 c.1282T>G; p.Y428D 
Missense 
mutation Po N > Po A 
Probably 
damaging 
Affects 
protein 
function 
Familial aortic aneurysm &/ dissection 
9 Exon 9 c.1460G>A; p.R487Q  
Missense 
mutation Po B > Po N 
Probably 
damaging Tolerated Suspected Marfan Syndrome 
  Notes : 
AA = Amino Acid 
PolyPhen = Polymorphisms Phenotyping 
SIFT = Sorting Intolerance from Tolerance 
PolyPhen and SIFT are prediction tools for predicting the functional effects of amino acid substitution  
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Explanation of the table and sequencing results : 
All of the mutations are missense mutations, in which a nucleotide substitution 
results in an amino acid change : 
1. The mutation is located in exon 2 of TGFBR1 gene, at the position 113 of 
cDNA, in which guanine is replaced by adenine, resulted in the change of 
amino acid 38 from cysteine (a polar-neutral amino acid) to tyrosine (a 
polar-neutral). This mutation is predicted to be probably damaging by 
PolyPhen and tolerated by SIFT. 
The position of mutation in gene sequence is shown below : 
 
 
 
 
 
 
 
 
Figure 7. Mutation c.113G>A; p.C38Y in TGFBR1 (forward sequence) 
Mutation in exon 2, showed a Cysteine (TGC) change to Tyrosine (TAC). 
 
2. The mutation is located in exon 3 of TGFBR1 gene, at the position 451 of 
cDNA, in which cytosine is replaced by timine, resulted in the change of 
amino acid 151 from arginine (a polar-basic amino acid) to cysteine (a 
polar-neutral amino acid). This mutation is predicted to be benign by 
PolyPhen and tolerated by SIFT. 
 
normal 
patient 
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The position of mutation in gene sequence is shown below : 
 
 
 
 
 
 
             
 
Figure 8. Mutation c.451C>T; p.R151C in TGFBR1 (forward sequence) 
Mutation in exon 3, showed an Arginine (CGC) change to Cysteine (TGC). 
 
3. The mutation is located in exon 4 of TGFBR1 gene, at the position 605 of 
cDNA, in which cytosine is replaced by timine, resulted in the change of 
amino acid 202 from alanine (a nonpolar-neutral amino acid) to valine (a 
nonpolar-neutral amino acid). This mutation is predicted to be benign by 
PolyPhen and affects protein function by SIFT. 
The position of mutation in gene sequence is shown below : 
 
 
 
 
 
            
  
Figure 9. Mutation c.605C>T; p.A202V in TGFBR1 (forward sequence) 
Mutation in exon 4, showed an Alanine (GCG) change to Valine (GTG). 
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4. The mutation is located in exon 5 of TGFBR1 gene, at the position 839 of 
cDNA, in which cytosine is replaced by timine, resulted in the change of 
amino acid 280 from serine (a polar-neutral amino acid) to leucine (a 
nonpolar-neutral amino acid). This mutation is predicted to be possibly 
damaging by PolyPhen and tolerated SIFT. 
The position of mutation in gene sequence is shown below : 
 
 
 
 
 
 
  
 
 
Figure 10. Mutation c.839C>T; p.S280L in TGFBR1 (reverse sequence) 
Mutation in exon 5, showed an Serine (TCA) change to Leucine (TGA), sequence shown 
in reverse. 
 
5. The mutation is located in exon 5 of TGFBR1 gene, at the position 958 of 
cDNA, in which adenine is replaced by guanine, resulted in the change of 
amino acid 320 from isoleucine (a nonpolar-neutral amino acid) to valine 
(a nonpolar-neutral amino acid). This mutation is predicted to be possibly 
damaging by PolyPhen and tolerated SIFT. 
 
 
 
normal 
patient 
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The position of mutation in gene sequence is shown below : 
 
 
 
   
 
 
  
 
Figure 11. Mutation c.958A>G; p.I320V in TGFBR1 (forward sequence) 
Mutation in exon 5, showed an Isoleucine (ATT) change to Valine (GTT). 
 
6. The mutation is located in exon 5 of TGFBR1 gene, at the position 965 of 
cDNA, in which guanine is replaced by adenine, resulted in the change of 
amino acid 322 from glycine (a nonpolar-neutral amino acid) to aspartic 
acid (a polar-acidic amino acid). This mutation is predicted to be benign 
by PolyPhen and tolerated by SIFT. 
The position of mutation in gene sequence is shown below : 
 
 
 
 
 
 
 
Figure 12. Mutation c.965G>A; p.G322D in TGFBR1 (forward sequence) 
Mutation in exon 5, showed a Glycine (GGT) change to Aspartic acid (GAT). 
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7. The mutation is located in exon 6 of TGFBR1 gene, at the position 980 of 
cDNA, in which cytosine is replaced by timine, resulted in the change of 
amino acid 327 from proline (a nonpolar-neutral amino acid) to leucine (a 
nonpolar-neutral amino acid). This mutation is predicted to be probably 
damaging by PolyPhen and affects protein function by SIFT. 
The position of mutation in gene sequence is shown below : 
 
 
 
 
 
 
 
 
 Figure 13. Mutation c.980C>T; p.P327L in TGFBR1 (forward sequence) 
Mutation in exon 6, showed a Proline (CCA) change to Leucine (CTA). 
 
8. The mutation is located in exon 8 of TGFBR1 gene, at the position 1282 of 
cDNA, in which timidine is replaced by guanine, resulted in the change of 
amino acid 428 from tyrosine (a polar-neutral amino acid) to aspartic acid 
(a polar-acidic amino acid). This mutation is predicted to be probably 
damaging by PolyPhen and tolerated by SIFT. 
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normal 
 58
Y D P L 
Y Y P L 
The position of mutation in gene sequence is shown below : 
 
 
 
 
 
 
  
 
 
 
Figure 14. Mutation c.1282T>G; p.Y428D in TGFBR1 (forward sequence) 
Mutation in exon 8, showed a Tyrosine (TAT) change to Aspartic acid (GAT). 
 
9. The mutation is located in exon 9 of TGFBR1 gene, at the position 1460 of 
cDNA, in which guanine is replaced by adenine, resulted in the change of 
amino acid 487 from arginine (a polar-basic amino acid) to glutamine (a 
polar-neutral amino acid). This mutation is predicted to be probably 
damaging by PolyPhen and tolerated by SIFT. 
The position of mutation in gene sequence is shown below : 
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Figure 15. Mutation c.1460G>A; p.R487Q in TGFBR1 (reverse sequence) 
Mutation in exon 9, showed an Arginine (CGG) change to Glutamine (CAG). 
 
Seven out of nine mutations occured at a well-conserved amino acid of 
the kinase domain. Mutations in exon 2 and exon 3 occured in the 
extracellular domain and cytoplasmic, intracellular domain, respectively. 
The distribution of mutations in each exon and domain are shown in figure 
10 below : 
 
 
 
 
 
 
 
Figure 16. Exons, domain organization and location of the mutations 
Note : extracellular domain (yellow), transmembrane domain (blue), serine-
threonine kinase domain (red), intracellular domain without specific function (grey) and 
glycine-serine-rich domain (green)7,17 
C38Y Y428D R487QR151C S280L I320V 
P327L G322D A202V 
patient 
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From the picture above we can see that most of the mutations are located in 
exon 5 (3 out of 9 different mutations).  
  We did the multiple alignment to see the conservation of TGFBR1 
across the species. The homologs for TGFBR1 are TGFBR1 in 
P.troglodytes, TGFBR1 in C.familiaris, Tgfbr1 in B.taurus, tgfbr1 in 
M.musculus, TGFBR1 in R.norvegicus, tgfbr1 in D.rerio, babo in 
D.melanogaster, AgaP_AGAP008247 in A.gambia, daf-1 in C.elegans. 
The multiple alignments are shown in Table 6 : 
 
Table 6. Multiple Sequence Alignment 
Alignment Protein Species 
C38 R151 A202 
TGFBR1 
TGFBR1 
TGFBR1 
TGFBR1 
Tgfbr1 
Tgfbr1 
TGFBR1 
tgfbr1 
babo 
AgaP_AGAP008247 
daf-1 
H. sapiens 
P. troglodytes 
C. familiaris 
B. taurus 
M. musculus 
R. norvegicus 
G. gallus 
D. rerio 
D. melanogaster
A. gambiae 
C. elegans 
LQCFCHLCT
LQCFCHLCT
LQCFCHLCT
LQCFCHLCT 
LQCFCHLCT 
LQCFCHLCT 
LQCFCHLCT 
LLCYCERCV
IKCHCDTCK
LKCHCDICK
EFLNETDRS 
ICHNRTVI 
ICHNRTVI 
ICHNRTVI 
ICHNRTVI 
ICHNRTVI 
ICHNRTVI 
LCHNRTVI 
MCHNRSII 
YCQRRARM 
***RRKRNS
DWYIRFKP 
RTIARTIV  
RTIARTIV 
RTIARTIV 
RTIARTIV  
RTIARTIV 
RTIARTIV 
RTIARTIV 
RTIARTIV  
RSIARQVQ 
RSIARQIQ 
LTIGGQIR 
Alignment Protein Species S280 I320 G322 
TGFBR1 
TGFBR1 
TGFBR1 
TGFBR1 
Tgfbr1 
Tgfbr1 
TGFBR1 
tgfbr1 
babo 
AgaP_AGAP008247 
daf-1 
H. sapiens 
P. troglodytes 
C. familiaris 
B. taurus 
M. musculus 
R. norvegicus 
G. gallus 
D. rerio 
D. melanogaster
A. gambiae 
C. elegans 
LWLVSDYHE
LWLVSDYHE
LWLVSDYHE
LWLVSDYHE
LWLVSDYHE
LWLVSDYHE
LWLVSDYHE
LWLVSDYHE
LWLVTDYHE
LWLVTDYHE
LWLVTEYHP
LHMEIVGTQ
LHMEIVGTQ
LHMEIVGTQ
LHMEIVGTQ
LHMEIVGTQ
LHMEIVGTQ
LHMEIVGTQ
LHMEIVGTQ 
LHMDIVGTR
LHMDIVGTR
LHNQIGGSK
LHMEIVGTQ 
LHMEIVGTQ 
LHMEIVGTQ 
LHMEIVGTQ 
LHMEIVGTQ 
LHMEIVGTQ 
LHMEIVGTQ 
LHMEIVGTQ 
LHMDIVGTR 
LHMDIVGTR 
LHNQIGGSK 
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Alignment Protein Species 
P327 R487 Y428 
TGFBR1 
TGFBR1 
TGFBR1 
TGFBR1 
Tgfbr1 
Tgfbr1 
TGFBR1 
tgfbr1 
babo 
AgaP_AGAP008247 
daf-1 
H. sapiens 
P. troglodytes 
C. familiaris 
B. taurus 
M. musculus 
R. norvegicus 
G. gallus 
D. rerio 
D. melanogaster
A. gambiae 
C. elegans 
GKPAIAHRD
GKPAIAHRD
GKPAIAHRD
GKPAIAHRD
GKPAIAHRD
GKPAIAHRD
GKPAIAHRD
GKPAIAHRD
GKPAIAHRD
GKPAIAHRD
NKPAMAHRD
LTALRIKKT
LTALRIKKT 
LTALRIKKT 
LTALRIKKT 
LTALRIKKT 
LTALRIKKT 
LTALRIKKT 
LTALRVKKS 
LTALRIKKT
LSSLRIKKT
FTSYICRKR
YYDLVPSDP 
YYDLVPSDP 
YYDLVPSDP 
YYDLVPSDP 
YYDLVPSDP 
YYDLVPSDP 
YYDLVPSDP 
YYDLVPSDP 
YYDVVQPDP 
FYDVVQPDP 
YIEWTDRDP 
 
multiple sequence alignment taken from  
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=homologene&dopt=MultipleAlignme
nt&list_uids=3177 )33 Notes : letters in red indicated the mutated amino acids.  
From this multiple alignment, it is shown that the mutated amino acid 
is highly conserved, and that TGFBR1 mutations occurred at evolutionary-
conserved domains. 
 
 Furthermore, 7 different polymorphisms in 6 different exons were 
found. and listed as below : 
Table 7. Polymorphisms found in this study 
No. 
Exon / 
Intron Polymorphism Found in 
1 1 c.70_78delGCGGCGGCG 63 patients 
2 4 c.805+39A>G  2 patients 
3 6 c.1125A>C p.T375T  2 patients 
4 7 c.1255+24G>A  72 patients 
5 7 c.1237C>A p.R413R 1 patient 
6 8 c.1386+90_94delTCTTT 64 patients 
7 9 g.45245A>G  66 patients 
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Explanation of the table, starts from the first polymorphism : 
1. Polymorphism 1 is located in exon 1, it is an in-frame deletion of 9 
bases starts from position 70 of cDNA until 78 (GCGGCGGCG), and 
causes deletion of 3 amino acid Alanin. 
2. Polymorphism 2 is located in intron 4, in the position of cDNA 
805+39, where adenine is replaced by guanine.  
3. Polymorphism 3 is located in exon 6, in the position of cDNA 1125, 
where adenine is replaced by cytosine. It is a silent mutation, because 
the nucleotide change results in the same amino acid, Threonine. 
4. Polymorphism 4 is located in intron 7, in the position of cDNA 
1255+24 where guanine is replaced by adenine.  
5. Polymorphism 5 is located in exon 7, in the position of cDNA 1237, 
where cytosine is replaced by adenine. It is a silent mutation, because 
the nucleotide change results in the same amino acid, Arginine. 
6. Polymorphism 6 is located in intron 8. It is a deletion of 5 bases 
(TCTTT) in the position of cDNA 1386+90 to 1386+94.  
7. Polymorphism 7 is located in intron 9, in the position of gDNA 45245, 
where adenine is replaced by guanine.  
These 7 polymorphisms have been previously reported in the Ensembl 
database of polymorphisms.29 
Three variants are left as unclassified (see table 5). They neither have 
been reported as polymorphisms, nor as mutations.  
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Table 8. Unclassified Variants (UV) 
No. Exon / Intron 
Unclassified 
Variants Found in Clinical Features 
1 2 c.343+46T>G 1 patient Skeletal abnormality and aortic aneurysm 
2 7 c.1255+103G>A 4 patients 
1. Joint hypermobility, aortic 
aneurysm, pneumothorax 
2. Familial aortic aneurysm 
3. Scoliosis, pectus excavatum, 
arachnodactily, narrow & high 
palate 
4. Pectus carinatum, flexible 
shoulder, tall & skinny 
3 8 c.1386+87_91delTTTTC 1 patient Joint hypermobility, aortic aneurysm 
 
 Explanation of the table, starts from the first UV : 
1. UV 1 is located in intron 2, in the position of cDNA 343+46, where 
timidine is replaced by guanine. This UV presents in patient with 
skeletal abnormality and aortic aneurysm. 
2. UV 2 is located in intron 7, in the position of cDNA 1255+103, where 
guanine is replaced by adenine. This UV presents in 4 patients with : 
1. Joint hypermobility, aortic aneurysm and pneumothorax. 
2. Familial aortic aneurysm. 
3. Scoliosis, pectus excavatum, arachnodactily, narrow and high 
palate. 
4. Pectus carinatum, flexible shoulder, tall and skinny. 
3. UV 3 is located in intron 8. It is a deletion of 5 bases (TTTTC), starts 
from c.1386+87 to 1386+91. This UV presents in patient with joint 
hypermobility and aortic aneurysm. 
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All of the Uvs are non-coding variants (located in intron, which are not 
code the amino acid). To decide the pathogenicity, they need to be analyzed 
on cDNA to see whether this UV affecting splice site, therefore tissue 
biopsies of these patients are needed to perform the analyses. The DNA of 
parents are unfortunately unavailable. 
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IV.3 Distribution of mutations on clinical diagnosis 
Table 9. TGFBR1 mutations on clinical diagnosis 
TGFBR1 MUTATIONS 
Detail 
NO. CLINICAL DIAGNOSIS NUMBER 
OF 
PATIENTS 
Total 
Exon Mutation Pathogenicity status 
1. Marfan Syndrome 10 0 - - - 
2. Suspected Marfan 
Syndrome 
78 6 1. Exon 3 
2. Exon 4 
3. Exon 5 
4. Exon 5 
5. Exon 6 
6. Exon 9 
c.451C>T; p.R151C 
c.605C>T; p.A202V 
c.839C>T; p.S280L 
c.958A>G; p.I320V 
c.980C>T; p.P327L 
c.1460G>A; p.R487Q 
Pathogenic 
Unlikely to be pathogenic 
Pathogenic 
Unlikely to be pathogenic 
Pathogenic 
Pathogenic 
3. Aortic aneurysm and or 
dissection 
60 1 1. Exon 5 c.965G>A; p.G322D Pathogenic 
4. Familial aortic aneurysm 
and or dissection 
42 3 1. Exon 2 
2. Exon 4 
3. Exon 8 
c.113G>A; p.C38Y 
c.605C>T; p.A202V 
c.1282T>G; p.Y428D 
Pathogenic 
Unlikely to be pathogenic 
Pathogenic 
5. Ectopia lentis 2 0 - - - 
6. Dural ectasia 1 0 - - - 
7. Joint hypermobility 1 0 - - - 
Most of the mutations occured in patients with suspected Marfan Syndrome, followed by familial cases of aortic aneurysms. None of the patient with classic 
MFS, ectopia lentis, dural ectasia or joint hypermobility has TGFBR1 mutation.
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IV.4 Clinical characteristics of patients carrying the mutations  
The clinical information has been collected from clinical phenotypes 
that have been mentioned in laboratory request.  
The first patient (II.4), who has the mutation c.113G>A, p.C38Y is a 
male, having a type A thoracic aorta dissection at age 46. No other features 
related to MFS, LDS, EDS Vascular type or other syndrome had been found. 
One of his brothers has a history of aortic dissection.  
 Pedigree : 
 
 
 
 
 
 
Figure 17. Pedigree of family 1 
Familial case of Thoracic aortic aneurysm, in which two members of the family have 
the same clinical feature 
 
Patient 2 (c.451C>T, p.R151C), male, 50 years old, has an thoracic 
aortic aneurysms and minor signs of MFS. His mother has valvular heart 
disease and his father died suddenly at the age  of 62 without any known 
cause.  
 
 
 
Notes : 
 
= Male, unaffected 
= Male, affected 
= Female, unaffected 
= Female, affected 
= Proband 
II:4
I:1 I:2
II:3II:1 II:2
aortic dissection
aortic dissection(deceased)(deceased)
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Patient 3 (I.2) who has mutation c.605C>T, p.A202V, is a female, 57 
years old with thoracic aortic dissection. No other feature related to MFS, 
LDS, EDS vascular type or other syndrome has been found. She had a son 
who died earlier because of thoracic aortic dissection at age 23. Her 
daughter is healthy. The same mutation did not appear in her daughter’s 
DNA. The presence or absence of this mutation in her affected son will 
provide more information with regard to pathogenicity. Unfortunately, the 
DNA of her son is not available. 
 Pedigree of patient 3 : 
 
 
 
 
 
 
Figure 18. Pedigree of patient 3 
An autosomal dominant pattern of inheritance in which proband has child with the 
same features 
 
Patient 4 (III.1), female, 31 years old, has also the mutation c.605C>T, 
p.A202V. She was diagnosed as suspected MFS, unfortunately her clinical 
detail is not available. Her mother, maternal uncle and maternal grandmother 
have MFS. Unfortunately, they have passed away and there is no DNA 
available to perform further analysis.  
 
I:2I:1
II:1 II:2
aortic dissection
aortic dissection
(Deceased) 
Notes : 
 
= Male, unaffected 
= Male, affected 
= Female, unaffected 
= Female, affected 
= Proband 
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Figure 19. Pedigree of patient 4 
An autosomal dominant pattern of inheritance in which proband and her previous 
generation have the same features 
 
Patient 5 (c.839C>T, p.S280L), male, 24 years old, has skeletal 
features of MFS. He is tall with thin and long extremities, contractures of the 
hands, recurrent shoulder luxations and arachnodactyly. No other features of 
MFS in other organ system have been found. No other member of his family 
is found to have the same features. 
Patient 6 (c.958A>G p.I320V) is a male 53 years old who was 
diagnosed as suspected MFS, unfortunately the clinical detail is not 
available. There is no other family member known to have the same 
features. Unfortunately, the detailed clinical information can not be 
provided. 
Patient 7 (c.965G>A, p.G322D), female, 43 years old, has a mild 
dilatation of the ascending aorta. In 2002, she was diagnosed with an 
abdominal aortic aneurysm requiring surgery and in the same year she had a 
III:1
II:1 II:2
I:1 I:2
II:3
suspected MFS
MFS? MFS?
MFS?
Notes : 
 
= Male, unaffected 
= Male, affected 
= Female, unaffected 
= Female, affected 
= Proband 
(Deceased) 
(Deceased) 
(Deceased) 
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Notes : 
 
type B aortic dissection. No other features of MFS, LDS, EDS vascular type 
or other syndrome have been found. None of her family has the same 
features as hers.  
Patient 8 (III.1) who has mutation c.980C>T, p.P327L is a 39 years old 
man with aortic root aneurysm and dissection, who had undergone 
replacement of aortic root. He has an increased arm span-height ration, his 
Beighton score is 2/9, and he has flat feet, positive left thumb sign, positive 
right wrist sign, myopia and few striae near axilla. His mother (II.2) has an 
aortic root dilatation, iris diaphania on temporal side, Beighton score 1/9 and 
positive right wrist sign. He has a maternal uncle (II.3) with aortic root 
dilatation (had undergone aortic root replacement) and maternal grandfather 
(I.1) who died because of aortic dissection. The DNA of mother and uncle 
showed the same mutation. The pedigree of this patient is shown below : 
 
 
 
 
 
 
 
 
 
Figure 20. Pedigree of Patient 8 
An autosomal dominant pattern of inheritance in which proband and her previous 
generation have the same features 
I:1 I:2
II:2 II:3 II:4II:1
III:1 III:3
III:2
aortic dissection, 
increased span-height ratio
fingers signs, Beighton score 2/9
myopia, striae
aortic dilatation
iris diaphania aortic dilatation
fingers signs
aortic dissection
= Male, unaffected = Male, affected = Female, unaffected
= Female, affected = Proband
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Patient 9 (II.1) who has mutation c.1282T>G, p.Y428D is male, 45 
years old diagnosed as having thoracic aortic aneurysm and dissection at the 
age of 35 years. His mother has a descending aortic aneurysm. No other 
features of MFS, LDS, EDS vascular type or other syndromes have been 
found. 
 
 
 
 
 
 
 
Figure 21. Pedigree of patient 9 
An autosomal dominant pattern of inheritance in which proband and have the same 
clinical feature  
 
Patient 10, (c.1460G>A, p.R487Q), female, 17 years old (IV.2), was 
diagnosed as having an aortic aneurysm and hypermobility of the joints at 
10 years old. Her brother (IV.1) carries the same mutation and also having 
aortic aneurysms. No other features of MFS were apparent in these two 
patients. The pedigree is depicted in figure 7. I.2 died of aortic dissection at 
the age of 36 years, II-2 at the age of 50 years, III-2 at the age of 21 years  
 
 
 
II:1
I:1 I:2
II:2
III:1III:2
descenden aortic aneurysm
aortic aneurysm & dissection
Notes : 
 
= Male, unaffected 
= Male, affected 
= Female, unaffected 
= Female, affected 
= Proband 
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Figure 10. Pedigree of patient 10 
Figure 22. Pedigree of patient 10 
An autosomal dominant pattern of inheritance in which proband, her sibling and her 
previous generation have the same clinical features 
 
The summary of clinical and molecular findings in patients carrying 
the mutations is shown in Table 9.  
 
 
 
 
 
 
I:1 I:2
II:2II:1
III:2 III:3III:1
IV:1 IV:2
aortic aneurysm
aortic aneurysm,
joint hypermobility
aortic dissection
aortic dissection
aortic dissection
Notes : 
 
= Male, unaffected 
= Male, affected 
= Female, unaffected 
= Female, affected 
= Proband 
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Table 10. Clinical Findings of Patients with TGFBR1 Mutations 
Patient Age (years) Nucleotide Change Clinical features FH 
1 58 c.113G>A;  p.C38Y thoracic aortic aneurysm + 
2 51 c.451C>T; p.R151C thoracic aortic aneurysm - 
3 57 c.605C>T; p.A202V thoracic aortic aneurysm and dissection + 
4 31 c.605C>T; p.A202V Suspected Marfan Syndrome (details unknown) + 
5 25 c.839C>T; p.S280L 
Tall, thin and long extremities, 
contracture of the hands, shoulder 
luxation habitualis, arachnodactily 
- 
6 53 c.958C>T; p.I320V Suspected Marfan Syndrome (details unknown) - 
7 43 c.965G>A; p.G322D 
abdominal aortic aneurysm requiring 
surgery, aortic dissection type B, 
ascendance aortic aneurysm 
- 
8 57 c.980C>T; p.P327L Aortic root aneurysms and minor signs of MFS + 
9 45 c.1282T>G; p.Y428D Aortic aneurysms + 
10 17 c.1460G>A; p.R487Q Aortic aneurysms and joint hypermobility + 
 
Note : FH = Family History 
(+) = present 
(-) = absent 
  
From the table above, it is shown that 7 out of 10 patients have aortic 
aneurysms as clinical features, and 6 patients have positive family history.  
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Chapter V 
DISCUSSION 
 
Most of the patients included in this study were those with suspected MFS 
with or without the presence of aortic aneurysm and/or dissection (78/194), aortic 
aneurysm and/or dissection (60/194), and familial cases of aortic aneurysm and/or 
dissection (42/194). The mutations found in this study is 10 mutations in 194 
samples (10/194). Previously published results by Singh et al (2006) and Loeys et 
al (2006) on MFS patients without FBN1 mutations, as reviewed by Mizuguchi T 
and Matsumoto N, yield 2/41 and 1/22, respectively.34 The study by Matyas et al 
(2006) has found 4.0% (3/70) TGFBR1 mutations on MFS-related patients 
without FBN1 involvement.11 Furthermore, combining the findings of TGFBR1 
mutations in LDS and Thoracic Aortic Aneurysms and Dissections (TAAD), it is 
very likely that TGFBR1 mutations do play role in the pathogenesis of MFS and 
related disorders through TGFβ signaling, although the frequency is not 
significant. Mutation analysis on TGFBR1 should be considered in MFS and its 
related disorders, without the presence of mutations in FBN1 and TGFBR2. 
All the mutations that have been found in this study are novel, except one 
mutation in exon 9 p.R487Q, so there is no previous publication about the 
pathogenicity of these mutations. The pathogenicity of mutations were analyzed 
based on the changes in amino acid, the amino acid conservation across the 
species, the protein domain where the mutation was occurred, in some patients we 
looked for the presence or absence of the mutation in affected or unaffected 
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family members respectively, and use internet-based prediction tools software 
PolyPhen and SIFT. The mutation p.C38Y is considered pathogenic from the 
multiple alignment analysis and PolyPhen analysis. The result from PolyPhen 
analysis predicted that the changes will disturb the formation of disulfide bond of 
the protein, thus will disturb the structure of the protein. The mutation p.R151C is 
predicted to be benign and tolerated by Polyphen and SIFT analysis, respectively. 
However, considering big changes in amino acid type and the domain 
conservation across multiple species, this mutation is considered as pathogenic. 
The mutation c.605C>T, p.A202V has been predicted to affect protein function 
based on SIFT analysis, but predicted as benign on PolyPhen. It occurred at a 
highly conserved domain. However, this mutation is unlikely to be pathogenic  
because the change in amino acid type is not significant. The mutation p.S280L is 
considered pathogenic because the change from serine to leucine is a significant 
change. Serine and threonine residues can be autophosphorylated, but not leucine. 
The mutation p.I320V occurred at highly conserved domain, predicted as possibly 
damaging by PolyPhen analysis and “tolerated” by SIFT analysis. However, this 
mutation is unlikely to be pathogenic  because the change in amino acid type is 
not significant. The mutation p.G322D is predicted to be benign and tolerated on 
PolyPhen and SIFT analysis. But it is considered pathogenic, because of the 
significant change in amino acid, the conservation in 11 different species and the 
occurrence in the protein kinase domain. In patient with mutation p.P327L, the 
DNA of affected mother and affected uncle showed the same mutation. This 
mutation is predicted to be probably damaging and affects protein function by 
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both PolyPhen and SIFT analysis. The location of this mutation in protein kinase 
domain and the high conservation across 11 species, make this mutation strongly 
suggested as pathogenic. The mutation p.Y428D is predicted to be probably 
damaging and affects protein function by PolyPhen and SIFT analysis, 
respectively. With regard to a big change in amino acid, this mutation is 
considered pathogenic. 
 Mutation p.R487Q has been found previously to be pathogenic in other 
studies.10,11,35 Akutsu et al (2007) found this mutation in patient with acute aortic 
dissection, mesenteric artery aneurysm and bilateral pneumothorax, without other 
features of MFS or LDS.34 Matyas et al (2006) found this mutation in patient with 
thoracic aortic aneurysm and dissection, also without any features of MFS and 
LDS.11 Loeys et al (2006) described this mutation in patients with thoracic aortic 
aneurysm and thoracic aortic dissection, without other features of MFS or LDS.10 
From those three previous publications, it seems that a mutation in this location 
causes aortic aneurysm and dissection, and is not likely to cause skeletal or eye 
abnormality. 
 Seven out of nine different mutations in this study occurred at highly 
conserved kinase domains, more specifically, the serine-threonine kinase domain. 
This domain is responsible for the formation of kinase, an enzyme that plays a 
role in cellular processes, including division, proliferation, apoptosis and 
differentiation.35 Most of the mutations in TGFBR1 that have been published are 
located in this domain.10,11,13,20 Thus, it is strongly suggested that this domain has 
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a very crucial role in the formation of TGFβR1 and mutations in this domain are 
pathogenic.  
A polymorphism in exon 1 (c.70_78delGCGGCGGCG), the 6Ala allele, 
was predicted to act as low penetrance allele of the clinical features in Marfan 
Syndrome.37 This 6Ala allele has been previously associated with a higher risk of 
colorectal cancer, breast cancer and ovarian cancer. 6Ala/6Ala Homozygosity 
even leads to higher risk than 6Ala/9Ala heterozygosity.38 Whether it acts in the 
same way in MFS and related disorders, however, needs a broader analysis which 
includes a large number of controls.  
Among 194 patients with MFS and related disorders, we found 10 patients 
carrying TGFBR1 mutations. Based on the data available, none of these patients 
was diagnosed clinically as MFS fulfilling the Ghent criteria, nor had features of 
LDS or  other syndromes. These diseases have common nature, that the features 
might be shown to be age-dependent, thus a clinical follow up should be provided 
to confirm present diagnosis. In this study, all patients are more than 17 years old. 
Since they already exceed pubertal ages, the chance for developing new feature is 
not likely. But the existing feature still should be monitored for developing worse.  
From 10 cases with TGFBR1 mutations (7 pathogenics, 3 non 
pathogenics), seven out of ten patients with TGFBR1 mutation have aortic 
aneurysm, with 3 of them also have minor features of MFS. Seven of them are 
familial cases. The exact phenotype due to TGFBR1 mutations cannot be clearly 
concluded, since these patients have features ranging from isolated aortic 
aneurysm to skeletal abnormalities. Singh et al found TGFBR1 mutations in 
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patients with typical Marfan Syndrome.19 Loeys et al, Akutsu et al, Drera et al 
found mutations in patients with features of Loeys-Dietz syndrome.21,35,39 Ades et 
al reported mutations in Furlong Syndrome.12 Matyas et al found it in even larger 
variety of clinical features variation: in TAAD, LDS and typical MFS patients.11  
Thus, it is suggested that mutations in TGFBR1 have variable clinical outcomes, 
indeed. The likeliness of patients with TGFBR1 mutation having aortic aneurysms 
might be one sign that lead us to do TGFBR1 mutation analysis in MFS and 
related disorders patient. It has been recognized also, that mutation in TGFBR 
genes rarely found in classic type of MFS. In this study we found none of patient 
with classic MFS has mutation in TGFBR. 
Marfan Syndrome, Loeys-Dietz Syndrome, Familial Thoracic Aortic 
Aneurysms and Dissections and other Marfan-related disorders are inherited in 
autosomal dominant manner. An individual whose parent is carrying a 
heterozygous mutation of the gene causing this disorder will have 50% chance to 
develop the disorder. In this study, 6 familial cases with TGFBR1 mutations have 
been found. In these families, genetic counseling should be provided to inform 
them about the risk and how to deal with the disorders in the future. The nature of 
MFS and aortic aneurysms is that the clinical presentations develops with age. 
Patients must be warned and counseled that once they are diagnosed, they need to 
be monitored for aortic widening, skeletal growth, etc. The medicinal treatment 
needs to be taken a life long, and surgical treatment may be needed. 
Furthermore, mutations in TGFBR genes are related with more severe 
vascular manifestation with probably a shortened life expectancy.7 In EDS 
 78
vascular type, there’s a shortened survival, with the mean age is 48 years. The 
presence of tissue fragility make it difficult to do aorta repair, and increase the risk 
of visceral rupture.40 Patients affected by Loeys-Dietz Syndrome have high risk of 
aortic aneurysm and dissection. But the repairing surgery is usually less 
complication and more successful in LDS compared to EDS vascular type.10 In 
this case, a careful recognition on clinical presentation and molecular examination 
play an important role.  
In the rest of the 184 patients, the causative gene responsible for their 
disorders has been left unknown. Further research on genes which play role in the 
TGF-β signaling pathway, such as LTBP4, or TGFB itself9 will be needed. In 
patients having aortic aneurysms, other candidate genes which play role in 
maintaining the aortic structure, such as COL3A1, ACTA2 and MYH1141,42 may 
also be involved.  
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Chapter VI 
CONCLUSION AND SUGGESTION 
 
VI.1 CONCLUSION 
1. Marfan Syndrome and related disorders patients who have no mutation 
in FBN1 and TGFBR2 genes, could be positive for TGFBR1 gene 
mutation. Missense mutation is the commonest type of mutation which 
could be found in these individuals.  
2. Among 9 different mutations found in this study, 7 mutations are 
considered pathogenic and 2 mutations are not pathogenic. 
3. Clinical features of patients carrying the mutation are ranging from 
suspected Marfan Syndrome to isolated aortic aneurysm. None of the 
patients with classic MFS has mutation in TGFBR1 gene. 
4. Most of the patients carrying the TGFBR1 gene mutation have aortic 
aneurysm as clinical feature.  
 
IV.2 SUGGESTION 
1. The mutation analysis in this study were done based on database 
references and software-based analysis. This still need a functional study 
to know the expression of TGF-β to confirm the pathogenicity of the 
mutations.  
2. Genotype-phenotype correlation would be better seen in a larger number 
of patients. Thus, more samples are needed to see the TGFBR1 mutation 
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frequency in higher population. The stricter inclusion criteria will be 
expected to have better conclusion in this matter, too. 
3. Better study design in which we can follow the disease progress in MFS 
and related disorders patients should be used to get better understanding 
on the involvement and the impact of TGFBR1 mutations in MFS and 
related disorders pathogenesis and severity. 
4. This field of research has large potential to be explored in Indonesian 
population. The DNA samples from Indonesian patients is needed to 
perform the research. Centers which provide DNA sequencing services 
should be available.  
5. When the cost of DNA sequencing becomes a major problem, mutation 
screening methods, such as MLPA (Multiplex Ligation Dependent Probe 
Amplification) may be considered. By mutation screening methods, the 
requirement for DNA sequencing can be significantly reduced. 
6. Mutation analysis in other genes should be done on the rest of patients 
whose cause of the disorders are still unknown.  
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Chapter VII 
SUMMARY 
 
Marfan Syndrome (MFS), a common autosomal dominant inherited disorder 
of fibrous connective tissue, mostly affects three organ systems : skeletal, ocular 
and cardiovascular system. Cardiovascular involvements, the aortic aneurysms 
leading to aortic dissection or rupture, is the most life-threatening.  
Diagnosis of MFS can be established by the Ghent criteria. However, the 
interpretation of these criteria is not always easy, due to the presence of many 
disorders which are clinically similar to MFS. Those disorders, termed as related 
disorders of MFS include Loeys-Dietz syndrome, Sphrintzen-Goldberg 
Syndrome, Familial Aortic Aneurysm, Bicuspid Aortic Valve with Aortic 
Dilatation, Familial Ectopia Lentis, MASS phenotype, Marfan Body Type, Mitral 
Valve Prolapse Syndrome, Congenital Contractural Arachnodactily (Beals 
syndrome), Stickler syndrome and Ehlers-Danlos syndrome. 
Previously, the pathogenesis of MFS was explained based on the concept of 
fibrillin-rich micro fibrils as purely architectural elements in the extra cellular 
matrix. Mutations in the fibrillin-1 gene (FBN1 gene), known to cause MFS, 
however, the mutations have not always been found in MFS patients.  
Recent findings on the pathogenesis of MFS demonstrate changes in growth 
factor signaling and other changes in matrix-cell interactions. Mouse models of 
MFS with FBN1 mutation which have lung emphysema as phenotypic 
manifestation, showed increased TGFβ signalling. The involvement of TGFβ-
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receptor gene mutation in MFS has been shown in a Japanese patient with MFS 
who had a balanced chromosomal translocation involving chromosome 3p24. This 
locus had been found to show genetic linkage with MFS in a large French 
pedigree. The breakpoint in the Japanese patient disrupted the TGFBR2 gene.  
The proteins fibrillin-1, TGFBR1 and TGFBR2 take part in transforming 
growth factors β (TGFβ) signaling, thus mutations in one of these gene could 
cause similar phenotypes. Mutation analysis on FBN1 and TGFBR2 genes in MFS 
and related disorders have been well established, and is important to distinguish 
those Marfan spectrum disorders from one and another. However, since there are 
still many cases without any mutation in either FBN1 or TGFBR2, mutation 
analysis on other candidate gene is needed to be performed. Mutation analysis on 
TGFBR1 gene as one of candidate gene, which include the recognition of 
mutation and its kind, the prediction on pathogenicity, the distribution of 
phenotypes on genotypes and the recognition of clinical sign which may lead to 
this gene, are need to be done. 
The TGFBR1 gene is also known as activin A receptor like kinase, or serine 
/ threonine-protein kinase receptor R4 gene. The DNA size is approximately 45kb 
long, the mRNA size is 2308bp, contains of 9 exons and is located on 
chromosome 9q22.33. The protein domains of TGFBR1 consist of extra cellular 
domain, transmembrane domain, cytoplasmic domain, glycine-serine rich domain, 
and serine-threonine kinase domain. These domains are highly conserved across 
species. 
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This research is in the field of medical genetics, held in the DNA Diagnostic 
Laboratory of Vrije Universiteit Medisch Centrum (VUmc), Amsterdam, The 
Netherlands. This is a descriptive study. The population of this research is the 
DNA samples of patients with Marfan Syndrome and related disorders which have 
been reffered to DNA Diagnostic Laboratory of VUmc Hospital Amsterdam, The 
Netherlands from the year 1998-2008. The DNA samples were donation with 
permission from Gerard Pals, PhD as the principal investigator of Connective 
Tissue Disorders research in the DNA Diagnostic Laboratory of VUmc Hospital 
Amsterdam, The Netherlands. All of the samples used in this research are part of 
Connective Tissue Disorders research project, and have been consent to be 
included in research. 
One hundred and ninety four DNA of unrelated patients with MFS, 
suspected MFS, or related disorders, have been included. The inclusion criteria 
were having at least one major criterion of MFS and found to be negative for 
FBN1 and TGFBR2 mutations on previous examination. The samples were 
excluded if the amount of the DNA were not enough for further analysis. The 
phenotypic characteristics of the patients were then traced from their laboratory 
request form.  
PCR was done to amplify the whole 9 exons of TGFBR1. The PCR products 
were then confirmed by gel electrophoresis, and underwent a pre-sequencing 
preparation before go to an automated sequencing machine. The results of the 
DNA sequencing were then analyzed for the presence of variants. When a variant 
has been found, the database of mutations and polymorphisms would be used to 
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confirm whether the variant is a mutation or polymorphism. When it was not in 
the database, then the following things would be considered to decide the 
pathogenicity : the amino acid changes, domain localization, conservation across 
species using multiple sequence alignment, and the prediction results from 
internet-based software : PolyPhen and SIFTblink.  
The patients were grouped into several diagnoses based on clinical findings 
and matched with Ghent Criteria. A diagnosis of MFS was based on Ghent 
Criteria. Incomplete Ghent Criteria, or having at least one major criterion in an 
organ system with minor criterion of another organ, or more than one minor 
criterion, would be considered as Suspected MFS. The patients with only specific 
clinical features (such as only has aortic aneurysm, ectopia lentis, dural ectasia or 
joint hypermobility) would be grouped as the clinical findings, recognized as 
Marfan Syndrome, Suspected MFS, Aortic Aneurysms and/ Dissections, Familial 
Aortic Aneurysms and/ Dissections, Ectopia Lentis, Dural Ectasia, Joint 
Hypermobility. There are 10 MFS, 78 Suspected MFS, 60 Aortic aneurysms and/ 
Dissections, 42 Familial aortic aneurysms and dissections, 2 Ectopia Lentis, 1 
Dural ectasia and 1 joint hypermobility patients. 
On sequencing all 9 exons of TGFBR1, a total of 9 mutations, 7 different 
polymorphisms and 3 unclassified variants in TGFBR1 were found. The mutations 
were found in 10 patients. The 9 mutations, occured in 7 different exons.  
The first mutation c.113G>A; p.C38Y is located in exon 2 of TGFBR1 gene, 
at the position 113 of cDNA, in which guanine is replaced by adenine, resulted in 
the change of amino acid 38 from cysteine (a polar-neutral amino acid) to tyrosine 
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(a polar-neutral), and is predicted to be pathogenic. This mutation is happened in 
patient with Familial aortic aneurysm and dissection. 
The mutation c.451C>T; p.R151C is located in exon 3 of TGFBR1 gene, at 
the position 451 of cDNA, in which cytosine is replaced by timine, resulted in the 
change of amino acid 151 from arginine (a polar-basic amino acid) to cysteine (a 
polar-neutral amino acid), and is predicted to be pathogenic. This mutation is 
present in patient with suspected MFS, with the clinical features aortic aneurysms 
and minor signs of MFS. 
The mutation c.605C>T; p.A202V is located in exon 4 of TGFBR1 gene, at 
the position 605 of cDNA, in which cytosine is replaced by timine, resulted in the 
change of amino acid 202 from alanine (a nonpolar-neutral amino acid) to valine 
(a nonpolar-neutral amino acid), and is predicted to be non pathogenic. This 
mutation occurs in patient with familial thoracic aortic aneurysms and dissection.  
The mutation c.839C>T; p.S280L is located in exon 5 of TGFBR1 gene, at 
the position 839 of cDNA, in which cytosine is replaced by timine, resulted in the 
change of amino acid 280 from serine (a polar-neutral amino acid) to leucine (a 
nonpolar-neutral amino acid), and is predicted to be pathogenic. This mutation 
happened in suspected MFS patient, with the clinical signs tall and long 
extremities, contractures of the hands, recurrent shoulder luxation and 
arachnodactyly. 
The mutation c.958A>G; p.I320V is located in exon 5 of TGFBR1 gene, at 
the position 958 of cDNA, in which adenine is replaced by guanine, resulted in 
the change of amino acid 320 from isoleucine (a nonpolar-neutral amino acid) to 
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valine (a nonpolar-neutral amino acid), and is predicted to be non pathogenic. 
This mutation occurred in patient with suspected MFS. 
The mutation c.965G>A; p.G322D is located in exon 5 of TGFBR1 gene, at 
the position 965 of cDNA, in which guanine is replaced by adenine, resulted in 
the change of amino acid 322 from glycine (a nonpolar-neutral amino acid) to 
aspartic acid (a polar-acidic amino acid), and is predicted to be pathogenic. This 
mutation occurred in patient with aortic aneurysms and dissections.  
The mutation c.980C>T; p.P327L is located in exon 6 of TGFBR1 gene, at 
the position 980 of cDNA, in which cytosine is replaced by timine, resulted in the 
change of amino acid 327 from proline (a nonpolar-neutral amino acid) to leucine 
(a nonpolar-neutral amino acid) and is predicted to be pathogenic. This mutation 
occurred in patient with suspected MFS, with aortic aneurysms and minor signs of 
MFS.  
The mutation c.1282T>G; p.Y428D is located in exon 8 of TGFBR1 gene, at 
the position 1282 of cDNA, in which timidine is replaced by guanine, resulted in 
the change of amino acid 428 from tyrosine (a polar-neutral amino acid) to 
aspartic acid (a polar-acidic amino acid), and is predicted to be pathogenic. This 
mutation occurred in patient with aortic aneurysms.  
The mutation c.1460G>A; p.R487Q is located in exon 9 of TGFBR1 gene, at 
the position 1460 of cDNA, in which guanine is replaced by adenine, resulted in 
the change of amino acid 487 from arginine (a polar-basic amino acid) to 
glutamine (a polar-neutral amino acid), and is a pathogenic mutation. This 
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mutation occurred in patient with aortic aneurysms and dissection with joint 
hypermobility. 
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ATTACHMENT 1 
Ghent Criteria of Marfan Syndrome5 
 
Diagnostic requirements : 
Index case: 
Major criteria in 2 different organ systems  
AND involvement of a third organ system.  
 
Relative of index case: 
1 major criterion in family history 
AND 1 major criterion in an organ system 
AND involvement in second organ system. 
 
SKELETAL 
 
Major (Presence of at least 4 of the following manifestations) 
 
__ pectus carinatum 
__ pectus excavatum requiring surgery 
__ reduced upper to lower segment ratio (Note 1)  
OR arm span to height ratio >1.05 
Height ____ Arm span ____ Upper segment ____ Lower segment ____ 
__ wrist (Note 2) and thumb (Note 3) signs 
__ scoliosis of >20° or spondylolisthesis 
__ reduced extension at the elbows (<170°) 
__ medial displacement of the medial malleolus causing pes planus 
__ protrusio acetabulae of any degree (ascertained on radiographs) 
 
Minor 
 
__ pectus excavatum of moderate severity 
__ joint hypermobility 
__ high arched palate with crowding of teeth 
__ facial appearance 
__ dolichocephaly, 
__ malar hypoplasia, 
__ enophthalmos, 
__ retrognathia, 
__ down-slanting palpebral fissures 
 
__ INVOLVEMENT: 2 major criteria or 1 major and 2 minor 
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OCULAR 
 
Major 
__ ectopia lentis 
 
Minor 
__ flat cornea 
__ increased axial length of the globe 
__ hypoplastic iris OR hypoplastic ciliary muscle causing decreased miosis 
 
__ INVOLVEMENT: 2 minor criteria 
 
CARDIOVASCULAR 
 
Major 
__ dilatation of the ascending aorta with or without aortic regurgitation 
and involving at least the sinuses of Valsalva 
__ dissection of the ascending aorta 
 
Minor 
__ mitral valve prolapse with or without mitral valve regurgitation 
__ dilatation of the main pulmonary artery, in the absence of valvular or 
peripheral pulmonic stenosis below the age of 40 years 
__ calcification of the mitral annulus below the age of 40 years 
__ dilatation or dissection of the descending thoracic or abdominal aorta 
below age of 50 years 
 
__ INVOLVEMENT: 1 minor criterion 
 
PULMONARY 
 
Minor (only) 
__ spontaneous pneumothorax 
__ apical blebs 
 
__ INVOLVEMENT: 1 minor criterion 
 
SKIN AND INTEGUMENT 
 
Minor (only) 
__ striae atrophicae 
__ recurrent or incisional hernia 
 
__ INVOLVEMENT: 1 minor criterion 
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DURA 
 
Major 
__ lumbosacral dural ectasia by CT or MRI 
 
 
FAMILY/GENETIC HISTORY 
 
Major 
__ first degree relative who independantly meets the diagnostic criterian. 
__ presence of mutation in FBN1 known to cause Marfan syndrome 
__ presence of haplotype around FBN1 inherited by descent and unequivocally 
associated with diagnosed Marfan syndrome in the family 
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ATTACHMENT 2 
DIAGNOSTIC CRITERIA OF SOME CONDITIONS OVERLAPPING 
WITH MARFAN SYNDROME 
 
1. Loeys-Dietz Syndrome 
General : 
- Widely-spaced eyes (hypertelorism),  
- Bifid uvula,  
- Generalized arterial tortuosity with widespread arterial aneurysms 
and dissection 
Loeys-Dietz Syndrome type 1 :  
- If craniofacial involvement consisting of cleft palate, 
craniosynostosis and hypertelorisms were observed 
Loeys-Dietz Syndrome type 2 : 
- No evidence of craniofacial involvement but only isolated bifid 
uvula 
 
2. Ehler-Danlos Syndrome  
General :  
- Skin hyperextensibility,  
- Joint hypermobility,  
- Easy bruising,  
- Tissue fragility,  
- Mitral valve prolapse,  
- Aortic dilatation (uncommon) 
- Chronic joint and limb pain 
Classic type : 
- Inheritance : autosomal dominant 
- Major criteria : skin hyperextensibility, widened atrophic scars, 
joint hypermobility 
 97
- Minor criteria : smooth, velvety skin, molluscoid pseudotumors, 
muscle hypotonia, easy bruising, hiatal hernia, anal prolapse, 
positive family history 
Hypermobility type : 
- Inheritance : autosomal dominant 
- Major criteria : hyperextensibility and or smooth velvety skin, 
generalized joint hypermobility 
- Minor criteria : recurring joint dislocation, chronic joint/limb pain, 
positive family history 
Vascular type : 
- Inheritance : autosomal dominant 
- Major criteria : thin, translucent skin, arterial/intestinal/uterine 
fragility or rupture, extensive bruising, characteristic facial 
appearance 
- Minor criteria : acrogeria, hypermobility small joints, tendon and 
muscle rupture, clubfoot, early-onset varicose veins, arteriovenous 
or carotid-cavernous sinus fistula, pneumothorax, gingival 
recession, positive family history 
 
3. MASS phenotype : 
- Mitral valve prolapse,  
- Aortic root diameter at the upper limit of normal, 
- Stretch mark (striae),  
- Skeletal features of Marfan (joint hypermobility, pectus 
excavatum/carinatum, scoliosis) 
 
4. Congenital Contractural Arachnodactily (Beals Syndrome)  
- Inability to fully extend multiple joints such as fingers, elbows, 
knees, toes, and hips 
- Crumpled ear 
- Arachnodactily 
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- Scoliosis 
- Kyphoscoliosis 
- Osteopenia 
- Dolichostenomelia 
- Pectus excavatum or pectus carinatum 
- Muscular hypoplasia 
- Micrognathia 
- High-arched palate 
 
5. Mitral Valve Prolapse Syndrome45 
Mitral valve prolapse with the signs : 
Auscultation : 
- Unequivocal mid- to late-systolic click, late systolic apical 
murmur, or both 
Echocardiographic : 
- Severe bowing of leaflets  
- Coaptation of leaflets on the atrial side of the mitral annulus 
- Moderate to severe Doppler mitral regurgitation with any leaflet 
bowing 
- Mild Doppler mitral regurgitation with moderate bowing 
 
6. Ectopia Lentis 
The displacement of the lens, also named dislocation or subluxation due to 
an increasing elongation of the zonula fibres.  
 
7. Dural Ectasia46 
Widening of dural sac, with the criteria (developed by Ahn et al) The 
sagittal width of the dural sac at S1 or below is greater than the width of 
the dural sac above L4, or the presence of anterior meningocele (major 
criterion). Minor criteria : a nerve root sleeve at L5 > 6.5 mm in diameter 
or scalloping at S1 > 3.5 mm.  
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8. Sphrintzen-Goldberg Syndrome 
- Omphalocele 
- Scoliosis 
- Laryngeal/pharyngeal hypoplasia 
- Mild dysmorphic face 
- Learning disabilities 
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ATTACHMENT 3 
DIAGNOSTIC CRITERIA OF AORTIC ANEURYSMS  
 
The classical approach to assess aortic root dimensions is to use M-mode 
echocardiography with measurements from the most anterior portion of the 
anterior aortic wall to the most anterior portion of the posterior aortic wall at end-
diastole; in subjects ≥ 16 years of age dilatation of the aortic root is present with at 
least two of the following criteria: 
1. width index of the aorta > 22 mm/m2, 
2. aortic diameter > 37 mm 
3. left atrial to aortic diameter ratio < 0.7.9 
In addition, M-mode nomograms are available to compare aortic root 
dimensions at the sinuses of Valsalva with body surface area. More recently, two-
dimensional echocardiography is used to assess aortic root dimensions at the level 
of the valve annulus, the aortic sinuses, the sinotubular junction and the proximal 
ascending aorta; such measurements are systematically larger (2 mm at the level 
of the aortic sinuses) than those made by M-mode echocardiography.   
Currently, two-dimensional echocardiography is used to diagnose aortic 
root dilatation by means of nomograms relating aortic root size to body surface 
area; such nomograms are available for children < 18 years of age, for adults < 40 
years of age and for adults ≥ 40 years of age;11 the use of these nomograms is 
recommended by the Ghent nosology and current European guidelines. In 
addition, adjusted nomograms are available for adults exceeding the 95th 
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percentile for body height (≥ 189 cm in men; ≥ 175 cm in women) and for 
children with suspected MFS (who are shown to present with a body surface area 
above the 50th percentile despite exclusion of MFS). 
Aortic ratios allow for comparison of individuals irrespective of age and 
body size. For calculation of an aortic ratio, the observed maximum diameter of 
the aortic root is divided by the predicted diameter based on age and body surface 
area (BSA) of normal individuals. The predicted sinus diameter (cm), for instance, 
can be calculated using the following regression formulas: 
• in children (age < 18 years) = 1.02 + (0.98 x BSA (m2)); 
• in adults (age 18-40 years) = 0.97 + (1.12 x BSA (m2)); 
• in adults (age ≥ 40 years) = 1.92 + (0.74 x BSA (m2)). 
Thus, an aortic sinus ratio of 1.3 indicates a 30 percent enlargement of the 
aortic sinus above the mean of normal individuals of the respective age and body 
surface area. Nomograms are less helpful in adults over 40 years of age, because 
obesity and aortic media degeneration account for a looser relationship between 
aortic size and body surface area; as a rule of thumb, in these individuals the 
aortic root is normal with diameters of < 37 mm, the ascending aorta is dilated 
with diameters ≥ 38 mm and < 50 mm, and aneurysm is present with diameters ≥ 
50 mm.  
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ATTACHMENT 4 
LABORATORY REQUEST FORM AND INFORMED 
CONSENT 
 
 
 
 
Afdeling Klinische Genetica   Aanvraag DNA- en 
eiwitdiagnostiek 
Sectie Genoomdiagnostiek 
 
Laboratorium voor DNA- en eiwitdiagnostiek 
Afdeling Klinische Genetica - VUMC 
Postbus 7057; intern BS7-J379 
1007 MB AMSTERDAM 
afleveradres voor koeriers: 
v.d. Boechorststraat 7, 3de etage kamer J379 
1081 BT AMSTERDAM 
Klinisch moleculair genetici 
Dr. E.A. Sistermans (hoofd) 
Dr. J.J.P. Gille (subhoofd) 
Dr. G. Pals (hoofd research) 
Dr. G.S. Salomons 
Secretariaat 
Tel : 020-4448346; Fax: 020-4448293 
E-mail: DNAdiagnostiek@vumc.nl 
website: www.vumc.nl/genoomdiagnostiek 
per persoon een aanvraagformulier invullen 
Secretariaat 
Tel : 020-4448346; Fax: 020-4448293 
E-mail: DNAdiagnostiek@vumc.nl 
website: www.vumc.nl/genoomdiagnostiek 
_______________________________________________________________________________
Aanvrager 
naam:      telefoonnummer: 
zh/instelling:     afdeling: 
adres:      uw referentie: 
plaats:      c.c. uitslag: 
_______________________________________________________________________________
Materiaal 
2 x 7 ml EDTA ontstold bloed (kleine kinderen 2 x 3 ml) voorzien van naam + geb. datum 
verzenden per post bij 
kamertemperatuur. Monsters die niet zijn voorzien van een deugdelijke identificatie worden 
geweigerd. Voor sommige 
indicaties is een huidbiopt of een fibroblastenkweek noodzakelijk (zie pag. 2). Datum afname: 
_______________________________________________________________________________
Indicatie 
Aangeven in de tabel op pagina 2. 
Relevante klinische gegevens: 
Vraagstelling 
 bevestigen/uitsluiten klinische diagnose  overig 
 prenataal onderzoek (vooraf aanmelden)  opslag, nl. voor: 
 screening op bekende mutatie in de familie, nl.: 
_______________________________________________________________________________
Is er al eens eerder materiaal van deze patiënt of van een familielid 
ingestuurd? 
 Nee 
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 Ja, nl. naam: geb. datum: ref. nr. 
Stamboom (eventueel aparte stamboom meesturen): 
 
 
 
 
 
 
 
 
 Betrokkene geeft geen toestemming voor anoniem gebruik van lichaamsmateriaal voor research 
(zie 5.3 op pag. 3). 
_______________________________________________________________________________
In te vullen door het laboratorium 
ZIS-nr.: 
familienummer: 
VD-nummer aanwezig materiaal: 
 
ontvangen materiaal:    paraaf staflid: 
 
Indicaties voor DNA-onderzoek 
 Achondroplasie (FGFR3) 
 Alzheimer 
 PSEN1 
 PSEN2 
 APP 
 Apert syndroom 
 Azoöspermie/oligospermie (CFTR) 
 Azoöspermie/oligospermie (AZFa/b/c deleties) 
 Basaal Cel Nevus syndroom (PTCH) 
 Birt-Hogg-Dubé syndroom (FLCN) 
 Blackfan-Diamond anemie (RPS19) 
 Borst- en ovariumkanker 
 BRCA1 
 BRCA2 
 BPES (Blepharophimosis, ptosis, en epicanthuis 
inversus syndroom; FOXL2) 
 CBAVD (CFTR) 
 Chorea, erfelijke benigne (TITF1) 
 Craniosynostose (FGFR2, TWIST) 
 Crouzon syndroom 
 Cystic fibrosis (CFTR) 
 Darmkanker, Lynch syndroom 
 MLH1 
 MSH2 
 MSH6 
 Darmkanker, MUTYH geassocieerde 
adenomateuze polyposis 
 DiGeorge syndroom (22q11-deletie) 
 Ehlers-Danlos syndroom 
 COL3A1 (fibroblastenkweek of huidbiopt nodig) 
 COL5A1 (fibroblastenkweek of huidbiopt nodig) 
 Elastine (ELN) 
 Fanconi anemie (alleen na overleg) 
 Fragiele X syndroom (FRAXA) 
 Frontotemporale dementie 
 MAPT 
 PGRN 
 CHMP2B 
 Gorlin syndroom (PTCH) 
 Hyperferritinemie-cataract syndroom (FTH1) 
 Hypochondroplasie (FGFR3) 
 Langer mesomele dysplasie (SHOX) 
 Loeys-Dietz syndroom 
 TGFBR1 
 TGFBR2 
 Marfan syndroom 
 FBN1 
 TGFBR2 
 Maternale contaminatie 
 MLPA microdeletie syndromen (o.a. 22q11 en 
Williams syndr.) 
 MLPA subtelomeren 
 Obesitas (MC4R) 
 Osteogenesis imperfecta 
 COL1A1 
 COL1A2 
 Parkinson, ziekte van 
 Parkin (Park2) 
 DJ-1 (Park7) 
 Pink1 (Park6) 
 SNCA (Park4) 
 LRRK2 (Park8) 
 Pelizaeus-Merzbacher, ziekte van (PLP1) 
 Pelizaeus-Merzbacher-like disease, autosomaal 
recessief (GJA12) 
 Peutz-Jeghers syndroom (STK11) 
 Pfeiffer syndroom (FGFR2, FGFR3) 
 Porencephalie (COL4A1) 
 Prematuur ovarieel falen (FMR1 premutaties) 
 Pulmonale arteriële hypertensie, idiopatische 
(BMPR2) 
 Schmid dysplasie (COL10A1) 
 Saethre-Chotzen syndroom (FGFR3/TWIST) 
 Surfactant proteïne B deficiëntie (SFTPB) 
 Thanatofore dysplasie (FGFR3) 
 Uniparentale disomie (UPD) 
 Van de Woude syndroom (IRF6) 
 Andere indicatie (alleen na telefonisch overleg) 
Overig DNA-onderzoek 
Onderzoek dat uitsluitend kan worden 
aangevraagd na overleg 
met prof. dr. M.S. van der Knaap, kinderneuroloog 
(ms.vanderknaap@vumc.nl) 
 Megalencephalic leukoencephalopathy with 
subcortical cysts (MLC1) 
 Leukoencephalopathie with vanishing white 
matter (VWM) 
 Leukoencephalopathy with brain stem and 
spinal cord involvement and lactate elevation 
(LBSL) 
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Onderzoek dat wordt verricht binnen het Metabool Laboratorium van het VUmc (Dr. G.S. Salomons) 
 
Hiervoor een ander formulier gebruiken dat kan worden aangevraagd bij g.salomons@vumc.nl 
• Alexander, ziekte van (GFAP) 
• Canavan, ziekte van (ASPA) 
• Cerebraal creatine deficiëntie syndroom (AGAT, GAMT, 
SLC6A8) 
• D-2-hydroxyglutaric dehydrogenase deficiëntie (D2HGDH) 
• Epilepsie, pyridoxine afhankelijke (ALDH7A1 
• GABA metabolisme (ALDH5A1, SSADH, GABA-T) 
• Glutaryl-CoA dehydrogenase deficiëntie (GCDH) 
• Homocysteine metabolisme (CBS, MTHFR,MMACHC) 
• L-2-hydroglutaric dehydrogenase deficiëntie, (L2HGDH) 
• Malonyl CoA decarboxylase deficiëntie (MLYCD) 
• Ribose-5-phosphate isomerase deficiëntie (RPI) 
• Tarui, ziekte van (PFKM) 
• Transaldolase deficiëntie (TALDO) 
• X-gebonden creatine transporter defect (SLC6A8) 
Indicaties voor eiwitonderzoek 
 Fibroblastenkweek voor enzymonderzoek elders* 
 Osteogenesis imperfecta, type ___* 
 Ehlers-Danlos syndroom type ___* 
 Primaire Ciliaire Dyskinesie/Kartagener syndroom (respiratoir epitheelbiopt nodig) 
* hiervoor is inzending van een fibroblastenkweek of een huidbiopt noodzakelijk 
 
Huidbiopten 
Afname: 
• huidbiopten onder steriele condities afnemen, na desinfectie met 70% alcohol (geen jodiumtinctuur) bij 
voorkeur aan de binnenkant van de onderarm of tijdens een operatie van de randen van de incisieplaats. 
• Het biopt opvangen in steriel kweekmedium (op verzoek kan dit toegezonden worden). Alleen in noodgevallen 
een steriele 
fysiologische zoutoplossing gebruiken. 
• Indien buiten normale laboratoriumwerktijden een biopt moet worden afgenomen, het materiaal bewaren bij 
kamertemperatuur 
(niet op ijs) en de volgende werkdag versturen. 
Verzending 
• het materiaal bij voorkeur op maandag, dinsdag of uiterlijk woensdag inzenden per TPG post. Op andere 
dagen alleen via een koerier. 
• het materiaal goed inpakken ter bescherming tegen breuk en forse temperatuurdalingen. 
• op het pakje vermelden “breekbaar” en “bewaren bij kamertemperatuur”. 
 
1. Aanvragen 
1.1. Om fouten en vertragingen te vermijden behoren aanvragen op een duidelijke en ondubbelzinnige 
wijze te worden ingediend. Door gebruik te maken van dit aanvraagformulier komen alle gewenste 
gegevens aan de orde. 
1.2. Met de acceptatie van een aanvraag verplicht de laboratorium zich tot het met zorg en vakmanschap 
uitvoeren van de gevraagde werkzaamheden volgens de voor de laboratorium geldende kwaliteitscriteria. 
1.3. Aanvragen kunnen worden geweigerd indien deze onvoldoende gegevens bevatten om een resultaat 
te kunnen bereiken dat voldoet aan de geldende kwaliteitscriteria. 
1.4. Het laboratorium moet in de gelegenheid gesteld te worden om met de aanvrager/behandelaar te 
kunnen overleggen over het gevraagde onderzoek. 
1.5. De aanvrager wordt verzocht om alvorens patiëntenmateriaal in te sturen, na te gaan of de 
betreffende patiënt is verzekerd voor klinisch genetische zorg. Indien na uitvoering van een verrichting de 
patiënt niet verzekerd blijkt, wordt de rekening naar de patiënt gestuurd. 
2. Monsters 
2.1. De aanvrager levert de te onderzoeken monsters aan bij het laboratorium, voorzien van een 
deugdelijke identificatie (naam en geboortedatum) en een volledig ingevuld aanvraagformulier. 
2.2. Per patiënt 2 x 7 ml EDTA bloed afnemen in onbreekbare buizen (geen glazen buizen), bij kleine 
kinderen 2 x 3 ml, en per post opsturen bij kamertemperatuur. 
2.3. Indien niet wordt voldaan aan het gestelde in 2.1 en 2.2 is het laboratorium niet gehouden het 
ingestuurde monster in ontvangst te nemen. 
2.4. Voor zover bij de indiening van de aanvraag daarover niets is overeengekomen, zal het laboratorium 
de monsters, c.q. de restanten daarvan na onderzoek, overeenkomstig de eigen voorschriften voor 
onbepaalde tijd bewaren. 
2.5. Alle handelingen en opslag voorafgaand aan de in ontvangstname van een monster vallen buiten de 
verantwoordelijkheid van het laboratorium. 
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3. Resultaten 
3.1. Resultaten in de vorm van onderzoeksuitslagen, adviezen, informatie of welke andere vorm dan ook, 
worden door het laboratorium in schriftelijke vorm aangeleverd. 
3.2. Resultaten komen doorgaans beschikbaar binnen: 
• Prenataal onderzoek: 2-3 weken 
• Presymptomatisch / dragerschapbepaling / bevestiging diagnose (bekende mutatie): 6-8 weken 
• Mutatie scanning (opsporen van nog onbekende mutatie): 3-6 maanden. In geval van spoed kunnen in 
overleg andere uitslagtermijnen worden afgesproken. 
4. Geheimhouding 
4.1. Geheimhouding van gegevens is gewaarborgd en vastgelegd in de ziekenhuisvoorschriften van het 
VU medisch centrum (zwijgplicht over patiëntengegevens). 
5. Gebruik patiëntenmateriaal 
5.1. Het laboratorium bewaart het verkregen DNA monster van de patiënt voor onbepaalde tijd tenzij een 
schriftelijk verzoek om het monster te vernietigen is ontvangen van de patiënt of diens wettelijke 
vertegenwoordigers. 
5.2. Het laboratorium gebruikt herleidbaar geanonimiseerd patiënten materiaal voor verder onderzoek 
(research) in lijn met de oorspronkelijke diagnostische vraagstelling. In geval dit resulteert in voor de 
patiënt relevante bevindingen zal deze via de oorspronkelijke aanvrager worden geïnformeerd. 
5.3. Voor het ontwikkelen van nieuwe en het verbeteren van bestaande technieken gebruikt het 
laboratorium herleidbaar geanonimiseerd patiëntenmateriaal, o.a. voor controles en validatie. Het 
laboratorium verzoekt de aanvrager de patiënt hierover te informeren. Mocht deze bezwaar maken tegen 
het anoniem gebruik van lichaamsmateriaal, dan kan dit op pagina 1 van het aanvraagformulier worden 
aangegeven. 
 
 
 
 
 
 
 
 
 
 
ATTACHMENT 5 
POLYPHEN USER’S GUIDE26 
 
POLYPHEN INPUT 
PolyPhen works with human proteins and identifies them either by ID or 
accession number from hs_swall database or by the amino acid sequence itself. 
In the latter case, PolyPhen tries to find exact match of the sequence in hs_swall. 
If a sequence is identified as a database entry, all entry information (complete 
sequence, FT, etc.) is used. Amino acid replacement is characterised by position 
number and substitution, consisting of two amino acid variants, AA1 and AA2. 
 
1. QUERY DATA 
The input form contains the following fields:  
Protein identifier (ACC or ID) from the SWALL database which is case-
insensitive, e.g., pexa_human, XYZ_HUMAN, P12345, p12345, aah01234, etc. 
PolyPhen maps this value to primary accession number and works with it.  
Amino acid sequence in FASTA format which should obey the "classical" 
FASTA format, e.g., provide sequence identifier  
User is supposed to complete only one of the fields above.  
Position is checked not to exceed the protein length  
Substitution is given by two amino acid variants; the first one is checked to 
correspond to the actual protein sequence, whereas the second is checked to differ 
from the first one.  
Description is an optional short string (up to 60 characters) providing descriptive 
name and/or comment for your query. It will be displayed in the query 
management page to facilitate identifying particular query instances which may be 
useful when you submit a large number of them.  
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2. OPTIONS 
Structural database (PDB/PQS)  
PolyPhen can use two protein structure databases, PDB and PQS. In general, 
queries against PDB can be faster than those against PQS. However, use of PQS 
(default) is strongly recommended if a user is concerned with residue contacts, 
especially inter-subunit.  
Sort hits by (Identity/E-value)  
Hits are sorted according to the sequence identity or E- value (default) of the 
sequence alignment with the input protein.  
Map to mismatch (No/Yes)  
By default, a hit is rejected if its amino acid at the corresponding position differs 
from the amino acid in the input sequence. Mapping to mismatching amino acid 
residue should be used with caution only when a protein with known structure and 
matching amino acid can not be found.  
Calculate structural parameters (For first hit only/For all hits)  
In some cases a user may want to check the conservation of structural parameters 
of a residue in all hits. By default, parameters are calculated for the first hit only, 
since they are expected to be very close in all homologous structures.  
Calculate contacts (For first hit only/For all hits)  
Contrary to the structural parameters, contacts are by default calculated for all 
found hits with known structure. This is essential for the cases when several 
PDB(PQS) entries correspond to one protein, but carry different information 
about complexes with other macromolecules and ligands (for example, see Fig.2 
in [Sunyaev et al 2001])  
Minimal alignment length (integer number, default: 100)  
PolyPhen will filter out hits with structure whose alignment length with the query 
sequence is smaller than the given value.  
 iii
Minimal identity in alignment (floating point value, not exceeding 1, default: 
0.5)  
Hits with structure whose sequence identity to the query sequence is smaller than 
the given threshold are filtered out  
Maximal gap length in alignment (integer number, default: 20)  
PolyPhen will filter out hits with structure whose alignment with the query 
sequence contains gaps with total length greater than this value  
Threshold for contacts (floating point value, default: 6.0Å)  
PolyPhen will report residue contacts below this threshold  
 
POLYPHEN OUTPUT 
PolyPhen output is divided into three main sections and consists mainly of the 
tables whose contents are discussed below. 
1.QUERY 
This section contains query data, mostly resembling the input:  
Acc 
number  
For entries from hs_swall this column contains link to the SRS 
system.  
Position  Substitution position.  
AA1  First amino acid variant.  
AA2  Second amino acid variant.  
Description  For entries from hs_swall this column contains protein description 
from the corresponding database field.  
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2.PREDICTION 
This section contains prediction itself, e.g., "This variant is predicted to be 
probably damaging", and the supporting information:  
Available 
data  
FT, alignment, structure  
Data available for prediction as described above  
Prediction  benign, possibly damaging, probably damaging, uknonwn: 
one of four predictions, also see above  
Prediction 
basis  
sequence annotation, sequence prediction, multiple alignment, 
structure: also see above  
Substitution 
effect  
For some rules predicting damaging effect, a brief description of 
expected effect is given. Hierarchy of possible damaging effects 
is given above . In this column PolyPhen also shows more 
"friendly" description of effect, e.g., Hydrophobicity change at 
buried site that corresponds to  
1.1.1. structural, buried site,hydrophobicity 
disruption  
Prediction 
data  
In case of a damaging substitution, this column summarises 
(mostly quantitative) data used to make a prediction, e.g.,  
Normed accessibility: 0.07, Hydrophobicity change: 1.3  
Remarks  Amino acid replacement features that were not used when making 
prediction, but may nevertheless be interesting, e.g., interchain 
contacts of a residue.  
 
 
PREDICTION 
The table below contains rules used by PolyPhen to predict effect of nsSNPs on 
protein function and structure. One row corresponds to one rule which may 
consist of several parts connected by logical "and". For a given substitution, all 
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rules are tried one by one, resulting in prediction of functional effect. If no 
evidence for damaging effect is seen, substitution is considered benign.  
Prediction basis and Substitution effect are described below.  
  RULES (connected with logical AND) 
  
PSIC 
score 
difference: 
Substitution 
site properties:
Substitution 
type 
properties: 
PREDICTION BASIS EFFECT 
1 arbitrary 
annotated as a 
functional site+ 
arbitrary 
probably 
damaging 
sequence 
annotation 
functional, 
functional site 
(2.2) 
2 arbitrary 
annotated as a 
bond formation 
site++ 
arbitrary 
probably 
damaging 
sequence 
annotation 
structural, bond 
formation (1.2) 
3 arbitrary 
in a region 
annotated as 
transmembrane 
possibly 
damaging 
sequence 
annotation 
4 arbitrary 
in a region 
predicted as 
transmembrane 
PHAT matrix 
difference 
resulting 
from 
substitution 
is negative 
possibly 
damaging 
sequence 
prediction 
functional, 
functional site, 
transmembrane 
(2.2.2) 
5 <=0.5 arbitrary arbitrary benign 
multiple 
alignment 
  
6 
atoms are closer 
than 3Å to 
atoms of a 
ligand 
arbitrary 
probably 
damaging 
structure 
functional, 
functional site, 
ligand binding 
(2.2.3) 
7 
>1.0 atoms are closer 
than 3Å to 
atoms of a 
residue 
annotated as 
BINDING, 
arbitrary 
probably 
damaging 
structure 
functional, 
functional site, 
indirect (2.1) 
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ACT_SITE, or 
SITE 
8 
change of 
accessible 
surface 
propensity is 
>=0.75 
possibly 
damaging 
structure 
structural, 
buried site, 
hydrophobicity 
disruption 
(1.1.1) 
9 
change of 
side chain 
volume is 
>=60 
possibly 
damaging 
structure 
structural, 
buried site, 
overpacking 
(1.1.2) 
10 
with normed 
accessibility 
<=15% 
change of 
side chain 
volume is 
<=-60 
possibly 
damaging 
structure 
structural, 
buried site, 
cavity creation 
(1.1.3) 
11 
change of 
accessible 
surface 
propensity is 
>=1.0 
probably 
damaging 
structure 
structural, 
buried site, 
hydrophobicity 
disruption 
(1.1.1) 
12 
change of 
side chain 
volume is 
>=80 
probably 
damaging 
structure 
structural, 
buried site, 
overpacking 
(1.1.2) 
13 
in the 
interval 
(0.5..1.5] 
change of 
side chain 
volume is 
<=-80 
probably 
damaging 
structure 
structural, 
buried site, 
cavity creation 
(1.1.3) 
14 
in the 
interval 
(1.5..2.0] 
with normed 
accessibility 
<=5% 
change of 
accessible 
surface 
propensity is 
>=1.0 
probably 
damaging 
structure 
structural, 
buried site, 
hydrophobicity 
disruption 
(1.1.1) 
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15 
change of 
side chain 
volume is 
>=80 
probably 
damaging 
structure 
structural, 
buried site, 
overpacking 
(1.1.2) 
16 
change of 
side chain 
volume is 
<=-80 
probably 
damaging 
structure 
structural, 
buried site, 
cavity creation 
(1.1.3) 
17 arbitrary arbitrary 
possibly 
damaging 
structure 
structural, 
buried site, 
cavity creation 
(1.1.3) 
18 >2.0 arbitrary arbitrary 
probably 
damaging 
multiple 
alignment 
  
+BINDING, ACT_SITE, SITE, MOD_RES, LIPID, METAL, SE_CYS  
++DISULFID, THIOLEST, THIOETH  
2.AVAILABLE DATA 
PolyPhen makes its predictions using three main source of data:  
(1) FT, sequence annotation (or prediction) being a fragment of SWALL feature 
table (FT) describing the substitution position,  
(2) alignment, PSIC profile scores derived from multiple alignment,  
(3) structure, structural information, obtained if a search against structural 
database was successful.  
The presence of all three data sources indicates the highest reliability of a 
prediction. However, as a rough estimate one can expect that approximately only 
~10% of all sequences have homologous proteins with known structure.  
2.PREDICTION BASIS 
As can be seen from the table above, a prediction is based on one of the following:  
• sequence annotation  
 viii
• sequence prediction  
• multiple alignment  
• structure  
depending on the rule used to make it. 
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ATTACHMENT 6 
SIFT USER GUIDE27 
 
SIFT takes a query sequence and uses multiple alignment information to predict 
tolerated and deleterious substitutions for every position of the query sequence. 
SIFT is a multistep procedure that (1) searches for similar sequences, (2) chooses 
closely related sequences that may share similar function to the query sequence , 
(3) obtains the alignment of these chosen sequences, and (4) calculates normalized 
probabilities for all possible substitutions from the alignment. Positions with 
normalized probabilities less than 0.05 are predicted to be deleterious, those 
greater than or equal to 0.05 are predicted to be tolerated.  
 
Procedure (the details): 
1. Get related sequences. A PSI-BLAST search against a database is executed 
on the query sequence.  
Parameters: 4 iterations, expectation value .0001, e-value threshold for 
inclusion in multipass model 0.002 
Update 05/15/01 Number of PSI-BLAST iterations reduced to 2 to save time 
and prevent the search from diverging. 
2. Choose closely related sequences. 
 
As described in Genome Research 11:963-87: We desire to have sequences 
that are similar in function as well as structure to the query sequence. To do 
so, we select only a subset of sequences from the PSI-BLAST results.  
a. Group sequences found from the PSI-BLAST search that are more than 
90% identical together and make a consensus sequence for each group by 
choosing the amino acid that occurs most frequently at each position. 
b. MOTIF finds conserved regions among the query sequence and the 
consensus sequences from (a) that were derived from at least two 
sequences. 
c. After the conserved regions in the query sequence have been identified by 
MOTIF, these regions are extracted from the sequences aligned by PSI-
BLAST. 
d. The conserved regions of the query sequence and those consensus 
sequences more than 90% identical are converted to a PSI-BLAST 
checkpoint file. 
e. The checkpoint file is given to PSI-BLAST to search among the remaining 
conserved regions of the consensus sequences not included in the seed 
checkpoint file. The top hit is added to the alignment corresponding tothe 
seed checkpoint file and the conservation over the entire alignment of 
conserved regions is calculated. If conservation does not decrease, the 
 x
consensus sequence is added to the alignment and the checkpoint file 
rebuilt. (e) iterates until conservation decreases.  
OR 
 
SIFT by conservation: In the original version of SIFT, an arbitrary 
number of sequences is added. In this version, sequences are continually 
added until they reach a sequence conservation cutoff, set by the user. 
If the sequences for which prediction is based on are very diverse (low 
conservation cutoff), only substitutions at the strongly conserved positions 
will be predicted as deleterious. If the sequences chosen for prediction are 
very similar to each other (high conservation cutoff), then most 
substitutions will be predicted as deleterious.  
Users can choose the degree of sequence conservation: they can opt for 
detecting most of the deleterious substitutions (use a high sequence 
conservation) , or predict fewer deleterious substitutions but with a high 
level of certainty (use a low sequence conservation).  
f. Group sequences found from the PSI-BLAST search (step 1) that are more 
than 90% identical together and make a consensus sequence for each 
group by choosing the amino acid that occurs most frequently at each 
position.  
g. The query sequence and its checkpoint file is given to PSI-BLAST to 
search among the consensus sequences. The top hit is added and aligned to 
the query sequence. Information is calculated for each position in the 
alignment, and the median of these values is obtained. If the median 
conservation over all positions does not fall below a given cuttoff, the hit 
is retained in the alignment and the checkpoint file rebuilt. The process 
repeats until the median conservations as long as the median information 
does not fall below the cutoff. 
 
The sequences picked from this iterative procedure are chosen as closely 
related sequences. You can also submit your own sequences. 
3. Obtain alignment. Since PSI-BLAST alignments are fairly accurate and long 
(Sauder & Dunbrack, 2000), we obtain the alignment of the sequences chosen 
in (2) from the initial PSI-BLAST search results (1). 
You can also submit your own alignment of your query sequence with other 
sequences. 
4. Calculate probabilities. At each position of the alignment, each amino acid i 
appears at a frequency ni. Using the ni's, the probabilities of amino acids are 
estimated according to Dirichlet mixtures (di's. The final probability of an 
amino acid appearing at a position, pi, is a weighted average of the observed 
 xi
frequencies and the Dirichlet estimation. The weight of the observed 
frequencies is the number of sequences used to construct the alignment. The 
weight of the Dirichlet estimated probabilities is an exponential function of a 
diversity measure (Div) calculated by 
Div = SUM ( ranki * ni)  
where ranki is the rank amino acid i has in reference to the original amino acid 
when BLOSUM62 substitution scores for the original amino acid are ranked 
from highest to lowest.  
Probabilities are normalized by dividing by max{Pr(amino acid)}. 
 
Update: 08/08/01: Prior to calculating the probabilities, sequences > 90% 
identical to the query sequence are removed. This eliminates the possibility 
that the sequence containing your substitution of interest is already 
represented in the database therefore and will trivially be predicted as 
tolerated. 
• We have found by comparison to experimental data that substitutions with 
less than 0.05 are deleterious. We use this as a cutoff for prediction. We 
strongly suggest users examine the normalized probabilities manually. If 
your substitutions are slightly above the 0.05 cutoff, you might want to 
consider this as a deleterious substitution.  
 
 
